Methods for improving site-specific integration frequency

JP2023550323A5Pending Publication Date: 2024-11-20MONSANTO TECHNOLOGY LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023528314
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-11
Filing Date
2021-11-10
Publication Date
2024-11-20

AI Technical Summary

Technical Problem

Site-specific integration frequencies in soybean and maize transformations are low, requiring extensive screening of primary transformants to identify desirable events, and current methods yield only a very low frequency of high-quality integration events.

Method used

The use of circularized T-DNA in Agrobacterium-mediated transformation, facilitated by Cre/lox recombination and inducible nucleases like LbCas12a, to achieve targeted integration at specific genomic sites, enhancing the frequency and quality of site-specific integration.

Benefits of technology

This method significantly improves the frequency and quality of site-specific integration in plant cells, reducing the need for extensive screening and ensuring precise insertion of transgenes, thereby minimizing deleterious effects on plant cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure relates to compositions and methods for improving site-specific integration frequency in the genome of plant cells.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of U.S. Provisional Application No. 63 / 112,438, filed November 11, 2020, which is incorporated herein by reference in its entirety.

[0002] Incorporation of sequence listings The Sequence Listing, which is 82,749 bytes (measured in MS-Windows®) and is contained under the file name "P34835WO00_SL.TXT", created on November 10, 2021, has been submitted electronically herewith and is incorporated by reference in its entirety.

[0003] Field The present disclosure relates to compositions and methods for improving site-specific integration frequencies using circular T-DNA. [Background technology]

[0004] background Site-specific integration (SDI) frequencies are very low in both soybean (Glycine max) and maize (Zea mays) transformation. Therefore, transformation of either soybean or maize requires screening a large number of primary transformants to identify SDI events. Methods to increase the absolute frequency of SDI, enrich for the regeneration of SDI events in primary transformants, or both are highly desirable.

[0005] Transfer DNA (T-DNA) is transferred from the tumor-inducing (Ti) plasmid of Agrobacterium to the nuclear DNA genome of the host plant. The T-DNA is inserted into the plant cell's genome by nicking the right border (RB) of the Ti plasmid, creating a region of single-stranded DNA from the left border (LB) of the T-DNA to the RB. After the RB is nicked, single-stranded DNA synthesis replaces the single-stranded DNA region, and the LB is nicked, allowing the single-stranded T-DNA fragment to be integrated into the plant cell's genome. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] No. 5,731,179 [Patent Document 2] U.S. Patent No. 6,265,638 [Patent Document 3] U.S. Patent Application Publication No. US2003 / 110532 [Patent Document 4] U.S. Patent Application Publication No. US2005 / 0183170 [Patent Document 5] U.S. Patent Application Publication No. US2007 / 0271627 [Patent Document 6] U.S. Patent Application Publication No. US2019 / 0211344 [Patent Document 7] U.S. Patent No. 6,437,217 [Patent Document 8] U.S. Patent No. 5,641,876 [Patent Document 9] U.S. Patent No. 6,426,446 [Patent Document 10] U.S. Patent No. 6,429,362 [Patent Document 11] U.S. Patent No. 6,232,526 [Patent Document 12] U.S. Patent No. 6,177,611 [Patent Document 13] U.S. Patent No. 5,322,938 [Patent Document 14] U.S. Patent No. 5,352,605 [Patent Document 15] U.S. Patent No. 5,359,142 [Patent Document 16] U.S. Patent No. 5,530,196 [Patent Document 17] U.S. Patent No. 6,433,252 [Patent Document 18] U.S. Patent No. 6,429,357 [Patent Document 19] U.S. Patent No. 5,837,848 [Patent Document 20] U.S. Patent No. 6,294,714 [Patent Document 21] U.S. Patent No. 6,140,078 [Patent Document 22] U.S. Patent No. 6,252,138 [Patent Document 23] U.S. Patent No. 6,175,060 [Patent Document 24] U.S. Patent No. 6,635,806 [Patent Document 25] U.S. Patent Application No. 09 / 757,089 [Patent Document 26] U.S. Patent No. 6,051,753 [Patent Document 27] U.S. Patent No. 5,378,619 [Patent Document 28] U.S. Patent No. 5,850,019 [Patent Document 29] U.S. Patent No. 5,159,135 [Patent Document 30] U.S. Patent No. 5,824,877 [Patent Document 31] U.S. Patent No. 5,591,616 [Patent Document 32] U.S. Patent No. 6,384,301 [Patent Document 33] U.S. Patent No. 5,750,871 [Patent Document 34] U.S. Patent No. 5,463,174 [Patent Document 35] U.S. Patent No. 5,188,958 [Patent Document 36] U.S. Patent No. 6,194,636 [Patent Document 37] U.S. Patent No. 6,232,526 [Patent Document 38] U.S. Patent and Trademark Publication No. 2004 / 0216189 [License 39] WO2019 / 084148 [License 40] US2020 / 0032289 [License 41] U.S. Patent No. 7,575,917 [License 42] WO2021026165 [Non-licensed literature]

[0007] [Non-licensed Document 1] "The American Heritage Science Dictionary" (edited by the American Heritage Dictionaries, 2011, published by Houghton Mifflin Harcourt, Boston and New York) [Non-licensed Document 2] "McGraw-Hill Dictionary of Scientific and Technical Terms" (6th edition, 2002, McGraw-Hill, New York) [Non-licensed Document 3] "Oxford Dictionary of Biology" (6th edition, 2008, Oxford University Press, Oxford and New York) [Non-licensed Document 4] Green and Sambrook, *Molecular Cloning: A Laboratory Manual*, 4th edition (2012); *Current Protocols in Molecular Biology* (edited by FM Ausubel et al. (1987)). [Non-licensed Document 5] Plant Breeding Methodology (NF Jensen, Wiley-Interscience (1988)) [Non-licensed Document 6] the series Methods In Enzymology (Academic Press, Inc.): PCR 2: A Practical Approach (edited by MJ MacPherson, BD Hames, and GR Taylor (1995)) [Non-licensed Document 7] Harlow and Lane, eds. (1988) Antibodies, A Laboratory Manual [Non-licensed Document 8] Animal Cell Culture (edited by RI Freshney (1987)) [Non-licensed Document 9] Recombinant Protein Purification: Principles And Methods, 18-1142-75, GE Healthcare Life Sciences [Non-licensed Document 10] CN Stewart, A. Touraev, V. Citovsky, T. Tzfira (eds.) Plant Transformation Technologies (Wiley-Blackwell) [Non-licensed Document 11] RH Smith (2013) Plant Tissue Culture: Techniques and Experiments (Academic Press, Inc.) [Non-licensed Document 12] Koukolikova-Nicola et al., Nature, 313-191~196 (1985) [Non-licensed Document 13] Singer et al., Plant Physiol., 160:511~522 (2012) [Non-licensed Document 14] Toro et al., PNAS; 85:8558~8562 (1988) [Non-licensed Document 15] Albert et al., 1995, Plant J., 7, 649-659

Non-licensed Document 16

Non-licensed Document 17

Non-licensed Document 18

Non-licensed Document 19

Non-licensed Document 20

Non-licensed Document 21

Non-licensed Document 22

Non-licensed Document 23

Non-licensed Document 24

Non-licensed Document 25

Non-licensed Document 26

Non-licensed Document 27

Non-licensed Document 28

[0008] Successful Agrobacterium-mediated transformation of plant cells typically results in random integration into the plant genome. Such random integration can have deleterious effects on the plant cell if the transgene is inserted into an essential endogenous gene. Similarly, such random integration can have deleterious effects on transgene expression due to positional effects on the chromosome into which the transgene is inserted. There is a need in the art for improved SDI via Agrobacterium-mediated transformation of plant cells. Previously, methods for site-specific integration (SDI) have been used that utilize Agrobacterium-mediated transformation and rely on a non-homologous end joining (NHEJ) strategy to integrate T-DNA into target sites cleaved by guided nucleases. However, this method produces a very low frequency (approximately 0.3%) of high-quality (e.g., single-transgene, full-length) SDI events in both maize and soybean. [Means for solving the problem]

[0009] Here, the present inventors have developed novel methods and compositions for improving SDI in Agrobacterium-mediated transformation using circularized T-DNA. [Brief explanation of the drawings]

[0010] [Figure 1A] Figure 1 includes Figures 1A and 1B. Figure 1A depicts a schematic diagram showing the arrangement of an Agrobacterium T-DNA vector containing expression cassettes for the aadA marker, LbCas12a protein, LbCas12a guide RNA, and a donor cassette for site-specific integration of the donor cassette into the GmTS1 target site. The donor cassette contains GOI-1 (gene of interest 1) flanked by target sites (represented by "X") recognized by the LbCas12a-gRNA complex. Pro denotes promoter. GOI = gene of interest. [Figure 1B] Figure 1 includes Figure 1A and Figure 1B. Figure 1B depicts a schematic diagram showing the arrangement of T-DNA integration at the GmTS1 site. LB and RB indicate the left and right border sequences of the T-DNA. Pro indicates the promoter. GOI = gene of interest. The dotted arrow indicates the RB-LB end junction. [Figure 2] Figure 2 shows a schematic diagram illustrating the aadA selectable marker cassette. P indicates promoter, L indicates leader, I indicates intron, CTP indicates chloroplast transit peptide, and T indicates terminator. [Figure 3] Figure 3 shows a schematic diagram showing the internal border sequence regions at the right border (RB) and left border (LB) and the deletion of said regions designed to result in less internal sequence region in the intron after splicing (Figure 2). [Figure 4] Figure 4 depicts a schematic diagram showing vectors containing RB and / or LB truncations, split marker cassettes, and target sites for CRISPR nucleases. [Figure 5] Figure 5 depicts a schematic diagram showing the configuration of an Agrobacterium T-DNA vector designed with two gRNAs expressed on the T strand: one targeting a unique site in the circularized T strand and one targeting a unique site in the genome. [Figure 6]Figure 6 shows a schematic diagram illustrating the configuration of an Agrobacterium T-DNA vector designed to generate circular substrates in vivo by Cre / lox recombination. Cre-mediated excision of the donor cassette from the T-DNA activates marker gene expression, which indirectly facilitates selection for events in which the donor-containing segment has been circularized. LB and RB indicate the left and right border sequences of the T-DNA. Pro = promoter; GOI = gene of interest. Horizontal arrows indicate the directionality of elements where directionality is important. [Figure 7] Figure 7 shows a schematic diagram illustrating the configuration of an Agrobacterium T-DNA vector designed to generate a circular substrate in vivo by Cre / lox recombination to facilitate targeted integration of a GOI cassette and a marker cassette at a genomic locus. LB and RB indicate the left and right border sequences of the T-DNA. Pro = promoter; GOI = gene of interest. [Figure 8A] Figure 8 depicts a schematic diagram showing two configurations (A and B) of Agrobacterium T-DNA vectors designed to generate circular substrates in vivo by the Cre / lox recombination system to facilitate targeted integration of a GOI cassette at a genomic locus. Cre-mediated excision of the P::GOI cassette activates LbCas12a gene expression. LB and RB indicate the left and right border sequences of the T-DNA. Pro = promoter; GOI = gene of interest. Horizontal arrows indicate the directionality of elements where directionality is important. [Figure 8B] Figure 8 depicts a schematic diagram showing two configurations (A and B) of Agrobacterium T-DNA vectors designed to generate circular substrates in vivo by the Cre / lox recombination system to facilitate targeted integration of a GOI cassette at a genomic locus. Cre-mediated excision of the P::GOI cassette activates LbCas12a gene expression. LB and RB indicate the left and right border sequences of the T-DNA. Pro = promoter; GOI = gene of interest. Horizontal arrows indicate the directionality of elements where directionality is important. [Figure 9]Figure 9 depicts a schematic diagram showing the configuration of an Agrobacterium T-DNA vector designed to generate a circular substrate by Cre / lox recombination to facilitate targeted integration of a GOI cassette and a marker cassette at a genomic locus. LB and RB indicate the left and right border sequences of the T-DNA. Pro = promoter; GOI = gene of interest. Horizontal arrows indicate the directionality of elements where directionality is important. [Figure 10] Figure 10 depicts a schematic diagram showing the arrangement of a vector containing two separate T-DNA regions: one containing a PRO::GOI1 cassette flanked by RB and LB elements, which may or may not be truncated as in Figure 3 and target sites for CRISPR nuclease, and a second T-DNA region containing a cassette for expression of CRISPR nuclease, gRNA, and a selectable marker gene. [Figure 11] FIG. 11 depicts a schematic diagram showing the configuration of a vector containing two separate T-DNA regions as in FIG. 10, except that in this embodiment the two separate T-DNA regions are on separate replicons. [Figure 12A] Figure 12 comprises Figure 12A and Figure 12B. Figure 12A depicts a schematic diagram showing the arrangement of vectors to reduce backbone-containing events. Partial marker: A partial fragment of the 3' marker gene cassette. [Figure 12B] Figure 12 comprises Figure 12A and Figure 12B. Figure 12B depicts a schematic diagram showing the arrangement of vectors to reduce backbone-containing events. Partial marker: A partial fragment of the 3' marker gene cassette. [Figure 13] Figure 13 depicts a schematic diagram showing the configuration of vectors for directed site-specific integration by homologous recombination: HR1: homology arm 1, HR2: homology arm 2. [Figure 14]Figure 14 depicts the initial DNA ends for hypothetical chromosome and donor DNA, sharing a common 5-nucleotide element (bold text). The embodiments shown in A and B are blunt-ended, although staggered embodiments are contemplated (as is the case for LbCas12a-mediated integration). The initial ends may be subject to some amount of "unraveling" or "chewback" from the original cut site before being joined together. The embodiment shown in 14A results in a junction where all positions are clearly attributable to the origin of the chromosome (top case) or donor (bottom case). The embodiment shown in 14B results in a junction where the 5-bp region (top case and bold) has an uncertain origin (e.g., could originally have come from either parental strand). [Figure 15] Figure 15 depicts examples of possible microhomology pathways. 15A depicts blunt-end ligation of ends that can reconstitute ambiguous regions ("artificial microhomology"). 15B depicts "sticky end" annealing and ligation ("full microhomology"), where 5'- or 3'-overhanging single-stranded DNA regions anneal perfectly. 15C depicts ligation of the 5'- or 3'-single-stranded ends of partial chewbacks, resulting in one or more base pairings at the ends of the strands, followed by hypothetical filling and ligation of base pairs to complete the insertion. [Figure 16]Figure 16 depicts standard LbCas12a-mediated DNA cleavage. Cas12a cleaves at the 23-nt target region immediately preceding the PAM site (italics). When LbCas12a cleaves, it cleaves after position 19 on the top strand (also called the non-target strand) and after position 23 on the opposite strand (also called the target strand), generating a 4-nt 5' overhang on each strand. The solid arrow indicates the 23-mer target site on the DNA to be cleaved. The dashed arrow indicates the cleaved target site. The target sequence shown is for illustrative purposes only. The arrow points from the italicized PAM site to the end of the 23-mer target region. The 4-nt 5' overhang on the target strand and 19 nt of the target site are marked with a letter designation (here, "A"). The 4-nt 5' overhang on the non-target strand is marked with an A'. A' is the reverse complement of A and, theoretically, can perfectly reanneal with the A overhang. Singly underlined nucleotide = A. Doubly underlined nucleotide = A'. [Figure 17] Figure 17 shows circularized, cut, and linearized T-DNA insertions. Circularized and LbCas12a-cut T-DNAs predominantly insert in the reverse orientation. The sequence in uppercase font represents the T-DNA. The sequence in lowercase font represents the chromosomal DNA sequence. The solid arrow in the T-DNA (top panel) indicates the Cas12a target site. The T-DNA target sequence is shown in bold. The solid arrows in the second and third panels indicate the cut T DNA target site. The dashed arrow in the third panel indicates the cut target site on the chromosome. Circularized, correct insertions are predominantly in the reverse orientation, where the orientation of the remainder of the target region (solid arrow) in the T-DNA (top case) is opposite to the orientation of the remainder of the target region (dashed arrow) in the chromosome (bottom case), resulting in a junction between two slightly truncated A' regions at one end and two slightly more truncated A regions at the other. The underlined base pairs indicate microhomology at the A' / A' junction. The target sequences shown are for illustrative purposes only and the figures are not to scale. [Figure 18A]Figure 18A shows a representation of the GmTS1 target site and the resulting A' cleavage product in the chromosome and T-DNA. The PAM site is shown in italics, and the 23 bp target site is in bold. Positions 1-19 of the target site are associated only with the A cleavage product and are therefore shown only as N for clarity. Solid arrow: full-length A' overhang of the chromosomally targeted GmTS1. Dashed arrow: full-length A' overhang of the T-DNA copy of GmTS1. [Figure 18B] Figure 18B shows microhomology at A' / A' junctions when the target sites on the chromosome and T-DNA are the same GmTS1 site. Each box queries whether the ends can anneal and indicates the number of bp of possible annealing for all possible small truncations of the two A' regions. Four of the 16 combinations predict possible 1-bp end joining: a single AT pairing in two cases and a single CG pairing in two cases. [Figure 18C] Figure 18C depicts the GmTS1 target site on the chromosome and the engineered target site (GmTS1_4RC) on the T-DNA, along with a representation of the resulting A' cleavage products. The PAM site is shown in italics, and the 23 bp target site is in bold. Positions 1-19 of the target site are associated only with the A cleavage product and are therefore shown only as N for clarity. Positions 20-23 within the GmTS1_4RC target site are the reverse complement (RC) of positions 20-23 in GmTS1. [Figure 18D] Figure 18D shows the macrohomology potential at the A' / A' junction when the chromosomal target site is GmTS1 and the T-DNA target site is the engineered target site GmTS1_4RC. The macrohomology potential increased to 10 of 16 pairings, including 6 that were greater than 1 bp and capable of annealing. [Figure 19]Figure 19 depicts a schematic diagram showing the configuration of an Agrobacterium T-DNA vector designed to generate a circular substrate in vivo by the Cre / lox recombination system to facilitate targeted integration of a GOI cassette at a genomic locus. Cre-mediated excision of the P::GOI cassette activates gRNA expression. LB and RB indicate the left and right border sequences of the T-DNA. Pro = promoter; GOI = gene of interest. Horizontal arrows indicate the directionality of elements where directionality is important. [Figure 20] Figure 20 depicts a schematic diagram showing the configuration of vectors for directed site-specific integration by homologous recombination: HR-L: left homology arm, HR-R: right homology arm. [Figure 21] Figure 21 depicts a schematic diagram showing the configuration of vectors for directed site-specific integration by homologous recombination. HR1: homology arm 1, HR2: homology arm 2. [Figure 22] Figure 22 depicts a schematic diagram showing the configuration of an Agrobacterium T-DNA vector designed to generate a circular substrate in vivo by the Cre / lox recombination system to facilitate targeted integration of a GOI cassette at a genomic locus. After T-DNA integration, TALE (transcription activator-like effector) proteins bind to the TALE binding site (TBS) and drive transcription of Cre recombinase via the 35S minimal promoter (min35S). Cre-mediated excision of the Pro::GOI cassette removes the TBS from the Cre cassette, thereby restricting Cre expression. [Figure 23] Figure 23 depicts a schematic diagram showing the configuration of an Agrobacterium T-DNA vector designed to generate multiple circular substrates in vivo by the Cre / lox recombination system to facilitate targeted integration of a GOI cassette in a genomic locus vector. [Figure 24] FIG. 24 depicts a schematic diagram showing the configuration of an Agrobacterium T-DNA vector designed to generate a circular substrate in vivo using a viral replicon to facilitate targeted integration of a GOI cassette in a genomic locus vector. DETAILED DESCRIPTION OF THE INVENTION

[0011] overview In one aspect, the present disclosure provides a recombinant nucleic acid construct comprising: (a) a left border sequence; (b) a first recombination site and a second recombination site; (c) a target site for an inducible nuclease; (d) a gene of interest operably linked to a first promoter; and (e) a right border sequence, wherein the target site for the inducible nuclease and the gene of interest operably linked to the first promoter are located between the first recombination site and the second recombination site.

[0012] In one aspect, the present disclosure provides a recombinant nucleic acid construct comprising: (a) a left border sequence; (b) a first recombination site and a second recombination site; (c) a sequence of interest operably linked to a first promoter; (d) a target site for an inducible nuclease; (e) a second promoter; and (e) a right border sequence, wherein the sequence of interest operably linked to the first promoter and the target site for the inducible nuclease are located between the first recombination site and the second recombination site.

[0013] In one aspect, the present disclosure provides a recombinant nucleic acid construct comprising: (a) a left border sequence; (b) a first promoter; (c) a first recombination site and a second recombination site; (d) a target site for an inducible nuclease; (e) a sequence of interest operably linked to the second promoter; and (f) a right border sequence, wherein the target site for the inducible nuclease and the sequence of interest operably linked to the second promoter are located between the first recombination site and the second recombination site.

[0014] In one aspect, the present disclosure provides a recombinant nucleic acid construct comprising: (a) a first left border (LB) sequence; (b) a first recombination site and a second recombination site; (c) a sequence of interest operably linked to a first promoter; (d) a target site for an inducible nuclease; (e) a first right border (RB) sequence; (f) a second RB sequence; and (g) a second LB sequence, wherein the sequence of interest operably linked to the first promoter and the target site for the inducible nuclease are located between the first recombination site and the second recombination site.

[0015] In one aspect, the present disclosure provides a recombinant nucleic acid construct comprising: (a) a left border sequence; (b) a sequence encoding a selectable marker gene; (c) a first recombination site and a second recombination site; (d) a target site for an inducible nuclease; (e) a sequence of interest operably linked to a first promoter; (f) a second promoter; and (e) a right border sequence, wherein the second promoter and the selectable marker gene are in the same orientation, and the target site for the inducible nuclease and the sequence of interest operably linked to the first promoter are located between the first and second recombination sites.

[0016] In one aspect, the present disclosure provides a recombinant nucleic acid construct comprising: (a) a left border sequence; (b) at least one guide RNA operably linked to a first promoter; (c) a first recombination site and a second recombination site; (d) a target site for an inducible nuclease; (e) a sequence of interest operably linked to a second promoter; and (f) a right border sequence, wherein the sequence encoding the target site for the inducible nuclease and the sequence of interest operably linked to the second promoter is located between the first recombination site and the second recombination site.

[0017] In one aspect, the present disclosure provides a method of editing the genome of a plant cell, the method comprising: (a) providing at least one plant cell with any of the recombinant nucleic acid constructs provided herein; and (b) selecting at least one plant cell from step (a), wherein the at least one plant cell comprises a sequence of interest inserted into the genome of the plant cell.

[0018] In one aspect, the present disclosure includes a plant cell or plant comprising any of the recombinant nucleic acid constructs provided herein.

[0019] In one aspect, the disclosure provides a method comprising introducing any of the recombinant DNA constructs provided herein into a cell, wherein an inducible nuclease cleaves the target site for the inducible nuclease and the genomic target site, and a sequence of interest is inserted into the genomic target site.

[0020] In one aspect, the disclosure provides an engineered double-stranded donor DNA molecule comprising one or more target sites for an inducible nuclease adjacent to at least one sequence of interest, wherein the sequence of nucleotides 20-23 of the target strand within the one or more target sites for the inducible nuclease is the reverse complement of the sequence of nucleotides 20-23 of the target strand within the genomic target site.

[0021] Detailed Description Unless otherwise defined, all technical and scientific terms used have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Where a term is provided in the singular, the inventors also contemplate aspects of this disclosure described by the plural of that term. In the event of a discrepancy in terms and definitions used in references incorporated by reference, the terms used in this application shall have the definitions given herein. Other technical terms used have their ordinary meaning in the art in which they are used, as exemplified by dictionaries specific to various art fields, such as "The American Heritage® Science Dictionary" (edited by the American Heritage Dictionaries, 2011, Houghton Mifflin Harcourt, Boston and New York), "McGraw-Hill Dictionary of Scientific and Technical Terms" (6th ed., 2002, McGraw-Hill, New York), or "Oxford Dictionary of Biology" (6th ed., 2008, Oxford University Press, Oxford and New York). We do not intend to be limiting as to mechanisms or modes of action, and references thereto are provided for illustrative purposes only.

[0022] The practice of the compositions and methods described in this disclosure involves, unless otherwise indicated, conventional techniques of biochemistry, chemistry, molecular biology, microbiology, cell biology, plant biology, genomics, biotechnology and genetics, which are within the skill of the art. See, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual, 4th Edition (2012); Current Protocols in Molecular Biology (F.M. Ausubel et al., eds., 1987); Plant Breeding Methodology (N.F. Jensen, Wiley-Interscience, 1988); the series Methods in Enzymology (Academic Press, Inc.): PCR 2: A Practical Approach (M.J. MacPherson, B.D. Hames, and G.R. Taylor, eds., 1995); Antibodies, A Laboratory Manual (Harlow and Lane, eds., 1988); Animal Cell Culture (R.I. Freshney, eds., 1987); Recombinant Protein Purification: Principles and Methods, 18-1142-75, GE Healthcare Life Sciences; Plant Transformation Technologies (C.N. Stewart, A. Touraev, V. Citovsky, T. Tzfira, eds., 2011). (Wiley-Blackwell); and RH Smith (2013) Plant Tissue Culture: Techniques and Experiments (Academic Press, Inc.).

[0023] Any references cited herein, including, for example, all patents, published patent applications, and non-patent publications, are hereby incorporated by reference in their entirety.

[0024] Where a grouping of options is presented, any and all combinations of the members comprising the grouping of options are specifically contemplated. For example, if an item is selected from the group consisting of A, B, C, and D, we specifically contemplate each option individually (e.g., A alone, B alone, etc.), as well as combinations of A, B and D; A and C; B and C, etc. The term "and / or," when used in a list of two or more items, means any one of the listed items by itself or in combination with any one or more of the other listed items. For example, the phrase "A and / or B" is intended to mean either or both A and B, i.e., A alone, B alone, or a combination of A and B. The phrase "A, B, and / or C" is intended to mean A alone, B alone, C alone, a combination of A and B, a combination of A and C, a combination of B and C, or a combination of A, B, and C.

[0025] Where numerical ranges are provided herein, it is understood that the range includes the endpoints of the range, and any number between the defined endpoints. For example, "1 to 10" includes any number between 1 and 10, as well as the number 1 and the number 10.

[0026] As used herein, singular terms and the singular forms "a," "an," and "the," for example, include plural referents unless the content clearly dictates otherwise.

[0027] Many methods can be used to transform plant cells. One common method involves the use of Agrobacterium tumefaciens, which can insert a segment of transfer DNA (T-DNA) from a tumor-inducing (Ti) plasmid into the genome of a plant cell. The T-DNA is inserted into the genome of a plant cell by nicking the right border (RB) of the Ti plasmid, creating a region of single-stranded DNA (referred to as the "T strand") from the left border (LB) of the T-DNA to the RB. After the RB is nicked, single-stranded DNA synthesis replaces the single-stranded DNA region, and the LB is nicked, allowing the single-stranded T-DNA fragment to be incorporated into the genome of the plant cell.

[0028] Despite the widespread use of Agrobacterium-mediated transformation, one major drawback is the inability to control the location where the T-DNA is inserted into the genome of a plant cell. Therefore, the applicant has developed a composition for increasing the targeted, site-specific integration of T-DNA into the genome of a plant cell using Agrobacterium-mediated transformation.

[0029] T strands are known to circularize. See Koukolikova-Nicola et al., Nature, 313-191-196 (1985). The junction sequence of circular T strands resides precisely within the 25-nucleotide direct repeats typically found at the ends of the T-DNA region of Ti plasmids, and evidence indicates that single-stranded T-DNA molecules are converted to double-stranded DNA (dsDNA) prior to integration. See Singer et al., Plant Physiol., 160:511-522 (2012). Singer et al. proposed that circularized dsDNA is a "dead-end" product that cannot insert into the plant genome.

[0030] Surprisingly, applicants have discovered a mechanism to revive "dead-end" circularized double-stranded T-DNA molecules, allowing them to integrate into the plant genome.

[0031] In one aspect, the present disclosure provides a recombinant nucleic acid construct comprising: (a) a left border (LB) sequence; (b) a first recombination site and a second recombination site; (c) a target site for an inducible nuclease; (d) a sequence of interest operably linked to a first promoter; and (e) a right border (RB) sequence, wherein the target site for the inducible nuclease and the sequence of interest operably linked to the first promoter are located between the first and second recombination sites. In some embodiments, the recombinant nucleic acid construct further comprises a sequence encoding at least one selectable marker gene, wherein the sequence encoding the at least one selectable marker gene comprises: (a) a second promoter; (b) at least one intron; and (c) a protein-coding sequence. In some embodiments, the second promoter is located between the sequence of interest and the RB sequence, and the protein-coding sequence is located between the LB sequence and the sequence of interest. In some embodiments, the LB sequence and the RB sequence are located between the second promoter and the protein-coding sequence. In some embodiments, the recombinant nucleic acid construct is circularized, and the second promoter sequence and the RB sequence are located 5' to the LB sequence. In some embodiments, the LB sequence and the RB sequence are both located 5' to the sequence of interest. In some embodiments, the recombinant nucleic acid construct comprises the following components in 5' to 3' order: a second promoter, a first recombination site, a target site for an inducible nuclease, a sequence of interest, a second recombination site, and at least one selectable marker gene, wherein the second promoter and the at least one selectable marker gene are in the same orientation. In some embodiments, the recombinant nucleic acid construct comprises the following components in 5' to 3' order: a first recombination site, at least one selectable marker gene, a target site for an inducible nuclease, a sequence of interest, a second promoter, and a second recombination site, wherein the second promoter and the at least one selectable marker gene are in the same orientation.

[0032] In one aspect, the present disclosure provides a recombinant nucleic acid construct comprising: (a) a left border (LB) sequence; (b) a first recombination site and a second recombination site; (c) a sequence of interest operably linked to a first promoter; (d) a target site for an inducible nuclease; (e) a second promoter; and (f) a right border (RB) sequence, wherein the sequence of interest operably linked to the first promoter and the target site for the inducible nuclease are located between the first recombination site and the second recombination site. In certain aspects, the recombinant nucleic acid construct further comprises a sequence encoding an inducible nuclease, wherein the sequence encoding the inducible nuclease comprises a first intron sequence and a second intron sequence. In one aspect, the recombinant nucleic acid construct comprises an LB sequence and an RB sequence located between a first intron sequence and a second intron sequence, the first intron sequence and the second intron sequence being located between a second promoter and a sequence encoding an inducible nuclease, and the second promoter being operably linked to the sequence encoding the inducible nuclease.

[0033] In one aspect, the present disclosure provides a recombinant nucleic acid construct comprising: (a) a left border sequence; (b) a first promoter; (c) a first recombination site and a second recombination site; (d) a target site for an inducible nuclease; (e) a sequence of interest operably linked to the second promoter; and (f) a right border sequence, wherein the target site for the inducible nuclease and the sequence of interest operably linked to the second promoter are located between the first and second recombination sites. In some embodiments, the recombinant nucleic acid construct further comprises at least one selectable marker gene operably linked to a third promoter. In some embodiments, the recombinant nucleic acid construct further comprises a sequence encoding a recombinase. In some embodiments, the recombinant nucleic acid construct further comprises a sequence encoding a guide RNA. In some embodiments, the recombinant nucleic acid construct further comprises a sequence encoding an inducible nuclease. In some embodiments, a recombinant nucleic acid construct comprises the following components in 5' to 3' order: a first promoter, a first recombination site, a target site for an inducible nuclease, a sequence of interest operably linked to a second promoter, a second recombination site, and a sequence encoding an inducible nuclease, wherein the first promoter and the sequence encoding the inducible nuclease are in the same orientation. In some embodiments, a recombinant nucleic acid construct comprises the following components in 5' to 3' order: a first promoter, a first recombination site, a target site for an inducible nuclease, a sequence of interest operably linked to a second promoter, a second recombination site, and a sequence encoding a gRNA, wherein the first promoter and the sequence encoding the gRNA are in the same orientation, and the sequence encoding the inducible nuclease is operably linked to a third promoter.In one embodiment, the recombinant nucleic acid construct comprises the following components in 5' to 3' order: a sequence encoding an inducible nuclease, a first recombination site, a selectable marker gene, a target site for the inducible nuclease, a sequence of interest operably linked to a second promoter, the first promoter, the second recombination site, and a third promoter, wherein the inducible nuclease-encoding sequence and the third promoter are in the same orientation, and the selectable marker gene and the first promoter are in the opposite orientation to the inducible nuclease-encoding sequence and the third promoter.

[0034] In one aspect, the present disclosure provides a recombinant nucleic acid construct comprising: (a) a first left border (LB) sequence; (b) a first recombination site and a second recombination site; (c) a sequence of interest operably linked to a first promoter; (d) a target site for an inducible nuclease; (e) a first right border (RB) sequence; (f) a second RB sequence; and (g) a second LB sequence, wherein the sequence of interest operably linked to the first promoter and the target site for the inducible nuclease are located between the first and second recombination sites. In some embodiments, the recombinant nucleic acid construct further comprises (h) a sequence encoding a guide RNA operably linked to a second promoter. In some embodiments, the recombinant nucleic acid construct further comprises (h) a sequence encoding at least one selectable marker gene operably linked to the second promoter. In some embodiments, the recombinant nucleic acid construct further comprises (h) a sequence encoding an inducible nuclease operably linked to the second promoter. In some embodiments, the recombinant nucleic acid construct comprises a sequence of interest located between a first LB sequence and a first RB sequence. In some embodiments, the recombinant nucleic acid construct comprises components (a), (b), (c), (d), (e), (f), and (g) physically linked to a single nucleic acid vector. In some embodiments, the recombinant nucleic acid construct comprises components (a), (b), (c), (d), (e), (f), and (g) and a sequence encoding a guide RNA operably linked to a second promoter physically linked to a single nucleic acid vector. In some embodiments, the recombinant nucleic acid construct comprises components (a), (b), (c), (d), (e), (f), and (g) and a sequence encoding at least one selectable marker gene operably linked to a second promoter physically linked to a single nucleic acid vector. In one embodiment, the recombinant nucleic acid construct comprises a sequence encoding components (a), (b), (c), (d), (e), (f), (g), and an inducible nuclease operably linked to a second promoter that is physically linked to one nucleic acid vector.In some embodiments, components (a), (b), (c), and (d) of the recombinant nucleic acid construct are physically linked to a first nucleic acid vector, and components (e), (f), and (g) of the recombinant nucleic acid construct are physically linked to a second nucleic acid vector. In some embodiments, components (a), (b), (c), and (d) of the recombinant nucleic acid construct are physically linked to a first nucleic acid vector, and components (e), (f), and (g) and a sequence encoding a guide RNA operably linked to a second promoter of the recombinant nucleic acid construct are physically linked to a second nucleic acid vector. In some embodiments, components (a), (b), (c), and (d) of the recombinant nucleic acid construct are physically linked to a first nucleic acid vector, and components (e), (f), and (g) and a sequence encoding at least one selectable marker gene operably linked to a second promoter of the recombinant nucleic acid construct are physically linked to a second nucleic acid vector. In one embodiment, components (a), (b), (c), and (d) of the recombinant nucleic acid construct are physically linked to a first nucleic acid vector, and components (e), (f), (g) and a sequence encoding an inducible nuclease, operably linked to a second promoter of the recombinant nucleic acid construct, are physically linked to a second nucleic acid vector.

[0035] In one aspect, the present disclosure provides a recombinant nucleic acid construct comprising: (a) a left border sequence; (b) a sequence encoding a selectable marker gene; (c) a first recombination site and a second recombination site; (d) a target site for an inducible nuclease; (e) a sequence of interest operably linked to a first promoter; (f) a second promoter; and (g) a right border sequence, wherein the second promoter and the selectable marker gene are in the same orientation, and the target site for the inducible nuclease and the sequence of interest operably linked to the first promoter are located between the first recombination site and the second recombination site.

[0036] In one aspect, the present disclosure provides a recombinant nucleic acid construct comprising: (a) a left border sequence; (b) at least one guide RNA operably linked to a first promoter; (c) a first recombination site and a second recombination site; (d) a target site for an inducible nuclease; (e) a sequence of interest operably linked to a second promoter; and (f) a right border sequence, wherein the sequence encoding the target site for the inducible nuclease and the sequence of interest operably linked to the second promoter is located between the first recombination site and the second recombination site.

[0037] In one aspect, the present disclosure provides a method for editing the genome of a plant cell, the method comprising: (a) providing at least one plant cell with any of the recombinant nucleic acid constructs provided herein; and (b) selecting at least one plant cell from step (a), wherein the at least one plant cell comprises a sequence of interest inserted into the genome of the plant cell. In certain aspects, the method further comprises (c) regenerating a plant from the at least one plant cell selected in step (b).

[0038] In one aspect, the present disclosure includes a plant cell or plant comprising any of the recombinant nucleic acid constructs provided herein.

[0039] As used herein, the term "recombinant" with respect to a nucleic acid (DNA or RNA) molecule, protein, construct, vector, etc., refers to a nucleic acid or amino acid molecule or sequence that is man-made and not normally found in nature and / or exists in a situation not normally found in nature, and includes nucleic acid (DNA or RNA) molecules, proteins, constructs, etc. that comprise combinations of polynucleotide or protein sequences that do not occur in nature in close proximity or close proximity together without human intervention, and / or polynucleotide molecules, proteins, constructs, etc. that comprise at least two polynucleotide or protein sequences that are heterologous with respect to each other.

[0040] In one aspect, the methods and compositions provided herein include a vector. As used herein, the term "vector" refers to a DNA molecule used as a vehicle to deliver exogenous genetic material to a cell. In some embodiments, the recombinant nucleic acid construct is provided in one vector. In some embodiments, the recombinant nucleic acid construct is provided in two or more vectors.

[0041] In some embodiments, one or more polynucleotide sequences from the recombinant nucleic acid construct are stably integrated into the genome of the plant. In some embodiments, one or more polynucleotide sequences from the vector are stably integrated into the genome of the plant.

[0042] In some embodiments, the first nucleic acid sequence and the second nucleic acid sequence are provided in a single vector, hi some embodiments, the first nucleic acid sequence is provided in a first vector and the second nucleic acid sequence is provided in a second vector.

[0043] As used herein, the term "T strand" refers to a single-stranded copy of DNA made when transcription is initiated from the right border (RB) DNA sequence of a vector. In naturally occurring Ti plasmids, transfer DNA (T-DNA) synthesis is initiated at a 25-base pair consensus DNA sequence called the "right border" (RB), and termination of T strand synthesis occurs at a 25-bp consensus DNA sequence called the "left border" (LB). Typically, the RB or LB sequence each comprises a 25-bp consensus DNA sequence and flanking DNA sequences at the 3' end, 5' end, or both. As used herein, "RB" or "LB" sequence refers to the 25-bp consensus DNA sequence and flanking DNA sequence, respectively. In some embodiments, the LB sequence is a truncated border sequence. In some embodiments, the RB sequence is a truncated border sequence. In some embodiments, the RB or LB DNA sequences provided herein can be of any length, such that the DNA segment is capable of transformation of plant tissue via Agrobacterium or other rhizobia-mediated methods (see U.S. Patent Nos. 5,731,179 and 6,265,638; and U.S. Patent Application Publication Nos. US2003 / 110532; US2005 / 0183170; US2007 / 0271627; and US2019 / 0211344). In some embodiments, the RB or LB DNA sequence comprises at least 25 nucleotides. In some embodiments, the RB or LB DNA sequence comprises at least 50 nucleotides. In some embodiments, the RB or LB DNA sequence comprises at least 100 nucleotides. In some embodiments, the RB or LB DNA sequence comprises at least 200 nucleotides. In some embodiments, the RB or LB DNA sequence comprises at least 300 nucleotides. In some embodiments, the RB or LB DNA sequence comprises at least 400 nucleotides. In some embodiments, the RB or LB DNA sequence comprises at least 500 nucleotides. In some embodiments, the RB or LB DNA sequence comprises at least 600 nucleotides.

[0044] As used herein, a "shortened border sequence" refers to a border sequence that is shorter than the native border sequence and contains a 25-bp consensus DNA sequence for either the RB DNA sequence or the LB DNA sequence. As a non-limiting example, if the native RB DNA sequence contains 300 nucleotides including the 25-bp consensus DNA sequence, a shortened RB DNA sequence contains 299 or fewer nucleotides, provided that the 25-bp consensus DNA sequence is still present. In one embodiment, a "shortened LB sequence" refers to a DNA sequence that contains the 25-bp consensus DNA sequence and a fragment from the flanking sequence located 5' to the LB consensus sequence. In one embodiment, a "shortened RB sequence" refers to a DNA sequence that contains the 25-bp consensus DNA sequence and a conserved "overdrive sequence" (see Toro et al., PNAS; 85:8558-8562 (1988)). In another embodiment, a "truncated RB sequence" refers to a DNA sequence that includes a fragment from the 25 bp consensus DNA sequence, a conserved "overdrive" sequence, and a flanking sequence located 3' to the RB consensus sequence.

[0045] In some embodiments, a recombinant nucleic acid construct comprises at least one LB sequence. In some embodiments, a recombinant nucleic acid construct comprises at least two LB sequences. In some embodiments, a recombinant nucleic acid construct comprises at least three LB sequences. In some embodiments, a recombinant nucleic acid construct comprises at least one RB sequence. In some embodiments, a recombinant nucleic acid construct comprises at least two RB sequences. In some embodiments, a recombinant nucleic acid construct comprises at least three RB sequences.

[0046] Site-specific recombination occurs when DNA strand exchange occurs between DNA segments that share at least some sequence homology with each other. Site-specific recombinases can recognize and bind to "recombination sites," which are short, specific DNA sequences that are cleaved by the recombinase, allowing DNA strand exchange, followed by strand repair. Typically, each recombinase protein binds to a specific, unique recombination site. As used herein, "recombinase" refers to an enzyme that can catalyze site-specific integration events within DNA. Recombinases can excise DNA, insert DNA, invert DNA, translocate DNA, and / or exchange DNA.

[0047] Some recombinases are directed to T-DNA vectors containing a sequence of interest for site-specific integration located between the recombination sites. In some embodiments, the sequence of interest comprises one or more target sites for an inducible nuclease. In some embodiments, the T-DNA vector further comprises an expression cassette encoding the recombinase. In some embodiments, the T-DNA vector further comprises an expression cassette encoding an inducible nuclease, wherein the expression cassette encoding the inducible nuclease is disrupted by the sequence of interest and the integration site. In some embodiments, the T-DNA vector further comprises an expression cassette encoding a marker, wherein the expression cassette encoding the marker is disrupted by the sequence of interest and the integration site. In some embodiments, the T-DNA vector further comprises a split marker cassette.

[0048] In some embodiments, the recombinase is a tyrosine recombinase. In some embodiments, the tyrosine recombinase is selected from the group consisting of Cre recombinase and Flp recombinase. In some embodiments, the recombinase is Cre recombinase. Cre-lox is a site-specific recombination system derived from bacteriophage P1. Cre-lox can be used to insert, delete, or translocate nucleic acid sequences. In this system, Cre recombinase recombines pairs of lox nucleic acid sequences. Lox sites contain 34 nucleotides, and the first and last 13 nucleotides (arms) are palindromic. In some embodiments, the Cre recombinase protein binds to two lox sites on different nucleic acids and cleaves them at the lox sites. The cleaved nucleic acids are split together (translocated back and forth) to complete the recombination. In some embodiments, the Cre recombinase protein binds to two lox sites flanking the sequence of interest and excises a circle from the T-DNA containing the sequence of interest. In some embodiments, the sequence of interest contains a target site for an inducible nuclease.

[0049] In some embodiments, the T-DNA vectors described herein contain modified lox sites, such as lox66 and lox71 sites (see Albert et al., 1995, Plant J. 7, 649-659). Cre-mediated recombination between these modified lox sites results in one wild-type loxP and one double mutant lox66-71 site that displays very low affinity for Cre recombinase and is therefore unable to recombine at the loxP site.

[0050] In one embodiment, the recombinase is flippase (Flp). The Flp-FRT site-specific recombination system is derived from the 2μ plasmid from the baker's yeast Saccharomyces cerevisiae. Flp can induce recombination between flippase recognition target (FRT) sites. The FRT site contains 34 nucleotides. Flp binds to the "arms" of the FRT site (one arm is in the opposite orientation) and cleaves the FRT sites on either end of the intervening nucleic acid sequence. After cleavage, Flp recombines the nucleic acid sequence between the two FRT sites.

[0051] In some embodiments, the recombinase is a serine recombinase. In some embodiments, the serine recombinase is selected from the group consisting of PhiC31 integrase, R4 integrase, and TP-901 integrase. In some embodiments, the recombinase is PhiC31 integrase. In some embodiments, the recombinase is R4 integrase. In some embodiments, the recombinase is TP-901 integrase.

[0052] In some embodiments, the recombinase is Hin recombinase. In some embodiments, the recombinase is Dre recombinase. In some embodiments, the recombinase is KD recombinase. In some embodiments, the recombinase is B2 recombinase. In some embodiments, the recombinase is B3 recombinase. In some embodiments, the recombinase is λ integrase. In some embodiments, the recombinase is HK022 integrase. In some embodiments, the recombinase is HP1 integrase. In some embodiments, the recombinase is Tn3 resolvase. In some embodiments, the recombinase is Gin recombinase. In some embodiments, the recombinase is ParA resolvase. In some embodiments, the recombinase is γδ resolvase. In some embodiments, the recombinase is Bxb1 integrase.

[0053] In certain embodiments, the recombinase is selected from the group consisting of Cre recombinase, FLP recombinase, Gin recombinase, Tnp1 recombinase, Bxb1 integrase, phiC31 integrase, R4 integrase, and TP-901 integrase.

[0054] In some embodiments, a recombinant nucleic acid construct comprises at least one recombination site. In some embodiments, a recombinant nucleic acid construct comprises at least two recombination sites. In some embodiments, a recombinant nucleic acid construct comprises at least three recombination sites. In some embodiments, a recombinant nucleic acid construct comprises at least four recombination sites. In some embodiments, a recombinant nucleic acid construct comprises at least five recombination sites. In some embodiments, a recombinant nucleic acid construct comprises at least six recombination sites. When a recombinant nucleic acid construct comprises sequences encoding two or more recombinases, the recombinases can be identical to each other, or they can be two or more different recombinases.

[0055] In some embodiments, the recombination site comprises at least 10 nucleotides. In some embodiments, the recombination site comprises at least 20 nucleotides. In some embodiments, the recombination site comprises at least 30 nucleotides. In some embodiments, the recombination site comprises at least 40 nucleotides. In some embodiments, the recombination site comprises at least 50 nucleotides. In some embodiments, the recombination site comprises at least 60 nucleotides. In some embodiments, the recombination site comprises at least 70 nucleotides. In some embodiments, the recombination site comprises at least 80 nucleotides. In some embodiments, the recombination site comprises at least 90 nucleotides. In some embodiments, the recombination site comprises at least 100 nucleotides. In some embodiments, the recombination site comprises 10 to 200 nucleotides. In some embodiments, the recombination site comprises 10 to 150 nucleotides. In some embodiments, the recombination site comprises 10 to 100 nucleotides. In some embodiments, the recombination site comprises 10 to 75 nucleotides. In some embodiments, the recombination site comprises 10 to 50 nucleotides. In some embodiments, the recombination site comprises 25 to 200 nucleotides. In some embodiments, the recombination site comprises between 25 and 150 nucleotides. In some embodiments, the recombination site comprises between 25 and 100 nucleotides. In some embodiments, the recombination site comprises 34 nucleotides. In some embodiments, the recombination site comprises 48 nucleotides.

[0056] In some embodiments, the recombination sites are lox sites. In some embodiments, the lox sites are selected from the group consisting of loxP sites, lox2272 sites, loxN sites, lox511 sites, lox5171 sites, lox71 sites, lox66 sites, loxLTR sites, M2 sites, M3 sites, M7 sites, and M11 sites. In some embodiments, the recombination sites are FRT sites. In some embodiments, the recombination sites are attP sites. In some embodiments, the recombination sites are attB sites. In some embodiments, the recombination sites are Hin binding sites.

[0057] In some embodiments, the recombinant nucleic acid construct comprises a first recombination site and a second recombination site. In some embodiments, the first recombination site and the second recombination site are lox sites. In some embodiments, the first recombination site and the second recombination site are FRT sites.

[0058] In some embodiments, the first recombination site and the second recombination site are identical to each other. In some embodiments, the first recombination site and the second recombination site comprise identical sequences. In some embodiments, the first recombination site and the second recombination site comprise different sequences. In some embodiments, the first recombination site and the second recombination site are modified lox sites that can undergo only one round of Cre-mediated recombination, resulting in the generation of one wild-type lox site and one double mutant site that are incompatible with each other (see Albert et al., 1995, Plant J., 7, 649-659). In some embodiments, the first recombination site is lox66 and the second recombination site is lox71.

[0059] In certain embodiments, the first recombination site and the second recombination site are compatible with each other. As used herein, with respect to the first recombination site and the second recombination site, "compatible" means that the same recombinase can act at both recombination sites and promote recombination between them.

[0060] As used herein, an "inducible nuclease" refers to a nuclease that can bind to and cleave at or near a specific target site within a nucleic acid molecule (e.g., a target site for the inducible nuclease).

[0061] As used herein, with respect to proximity to a specific target site, "proximal" refers to within 250 nucleotides of the target site on either the 5' or 3' end of the target site.

[0062] In some embodiments, the present disclosure provides an inducible nuclease. In some embodiments, the present disclosure provides at least one inducible nuclease. In some embodiments, the present disclosure provides at least two inducible nucleases. In some embodiments, the present disclosure provides a nucleic acid sequence encoding the inducible nuclease. In some embodiments, the nucleic acid sequence encoding the inducible nuclease is operably linked to a promoter.

[0063] In some embodiments, the present disclosure provides a nucleic acid sequence encoding at least one inducible nuclease. In some embodiments, the present disclosure provides a nucleic acid sequence encoding at least two inducible nucleases. In some embodiments, the present disclosure provides a nucleic acid sequence encoding at least three inducible nucleases.

[0064] In certain embodiments, the sequence encoding the inducible nuclease comprises a first intron sequence and a second intron sequence.

[0065] The sequence to which an inducible nuclease binds and / or cleaves is referred to herein as a "target site for an inducible nuclease" or simply as a "target site." A target site located within a chromosome is referred to as a "genomic target site." For target sites cleaved by an RNA-guided nuclease, the target site comprises a PAM sequence and a sequence recognized by the spacer sequence of the guide RNA. In certain embodiments, the target site for the inducible nuclease is located in a recombinant nucleic acid construct. In certain embodiments, the target site for the inducible nuclease is located 5' to the sequence of interest. In certain embodiments, the target site for the inducible nuclease is located 3' to the sequence of interest. In certain embodiments, a recombinant nucleic acid construct provided herein comprises only one target site for an inducible nuclease. In certain embodiments, a recombinant nucleic acid construct provided herein lacks a second target site for an inducible nuclease. In certain embodiments, the target site for the inducible nuclease is located between a first recombination site and a second recombination site.

[0066] In some embodiments, the target site for the inducible nuclease is present in the genome of the plant. In some embodiments, the genome of the plant is a nuclear genome. In some embodiments, the genome of the plant is a mitochondrial genome. In some embodiments, the genome of the plant is a plastid genome. In some embodiments, the genome of the plant is selected from the group consisting of a nuclear genome, a mitochondrial genome, and a plastid genome.

[0067] In some embodiments, the same target site for the inducible nuclease is present in the plant genome and the recombinant nucleic acid construct. In some embodiments, the target site for the inducible nuclease in the plant genome and the target site for the inducible nuclease in the recombinant nucleic acid construct are identical. In some embodiments, the target site for the inducible nuclease in the plant genome and the target site for the inducible nuclease in the recombinant nucleic acid construct are not identical.

[0068] In some embodiments, the target site for an inducible nuclease comprises 18 nucleotides. In some embodiments, the target site for an inducible nuclease comprises 19 nucleotides. In some embodiments, the target site for an inducible nuclease comprises 20 nucleotides. In some embodiments, the target site for an inducible nuclease comprises 21 nucleotides. In some embodiments, the target site for an inducible nuclease comprises 22 nucleotides. In some embodiments, the target site for an inducible nuclease comprises 23 nucleotides. In some embodiments, the target site for an inducible nuclease comprises 24 nucleotides. In some embodiments, the target site for an inducible nuclease comprises 25 nucleotides.

[0069] In some embodiments, the target site for an inducible nuclease comprises at least 10 nucleotides. In some embodiments, the target site for an inducible nuclease comprises at least 15 nucleotides. In some embodiments, the target site for an inducible nuclease comprises at least 20 nucleotides. In some embodiments, the target site for an inducible nuclease comprises at least 25 nucleotides. In some embodiments, the target site for an inducible nuclease comprises at least 30 nucleotides. In some embodiments, the target site for an inducible nuclease comprises at least 40 nucleotides. In some embodiments, the target site for an inducible nuclease comprises at least 50 nucleotides. In some embodiments, the target site for an inducible nuclease comprises at least 60 nucleotides. In some embodiments, the target site for an inducible nuclease comprises at least 70 nucleotides. In some embodiments, the target site for an inducible nuclease comprises at least 80 nucleotides. In some embodiments, the target site for an inducible nuclease comprises at least 90 nucleotides. In some embodiments, the target site for an inducible nuclease comprises at least 100 nucleotides. In some embodiments, the target site for the inducible nuclease comprises at least 150 nucleotides. In some embodiments, the target site for the inducible nuclease comprises at least 200 nucleotides.

[0070] In some embodiments, the target site for the inducible nuclease comprises 10 to 250 nucleotides. In some embodiments, the target site for the inducible nuclease comprises 10 to 200 nucleotides. In some embodiments, the target site for the inducible nuclease comprises 10 to 100 nucleotides. In some embodiments, the target site for the inducible nuclease comprises 10 to 75 nucleotides. In some embodiments, the target site for the inducible nuclease comprises 10 to 50 nucleotides. In some embodiments, the target site for the inducible nuclease comprises 10 to 30 nucleotides. In some embodiments, the target site for the inducible nuclease comprises 10 to 25 nucleotides. In some embodiments, the target site for the inducible nuclease comprises 15 to 30 nucleotides. In some embodiments, the target site for the inducible nuclease comprises 15 to 20 nucleotides.

[0071] In some embodiments, the inducible nuclease is selected from the group consisting of an RNA-guided nuclease, a zinc finger nuclease (ZFN), a meganuclease, a transcription activator-like effector (TALE) nuclease (TALEN), and a TALE-like protein.

[0072] In some embodiments, the guided nuclease is an RNA-guided nuclease.In some embodiments, the RNA-guided nuclease is a CRISPR (clustered regularly interspaced short palindromic repeats) nuclease.CRISPR nuclease (for example, Cas12a, Cas9, CasX) is a protein found in bacteria, which is guided to target nucleic acid molecule by guide RNA (" gRNA "), where endonuclease can then cut one or two strands into target nucleic acid molecule.Although CRISPR nuclease originates from bacteria, many CRISPR nucleases have been shown to function in eukaryotic cells.

[0073] Without being limited by any particular scientific theory, CRISPR nuclease forms a complex with guide RNA (gRNA), which hybridizes with a complementary target site, thereby guiding the CRISPR nuclease to the target site. In Class II CRISPR-Cas systems, a CRISPR array containing a spacer is transcribed during an encounter with a recognized invasive DNA and processed into a small interfering CRISPR RNA (crRNA). The crRNA contains a repeat sequence and a spacer sequence complementary to a specific protospacer sequence in the invasive pathogen. The spacer sequence can be designed to be complementary to a target sequence in a eukaryotic genome.

[0074] CRISPR nucleases associate with their respective crRNAs in their active forms. CasX, like the class II endonuclease Cas9, requires another non-coding RNA component, termed a trans-activating crRNA (tracrRNA), to have functional activity. The nucleic acid molecules provided herein can combine a crRNA and a tracrRNA into a single nucleic acid molecule, termed a "single guide RNA" (sgRNA) herein. Cas12a does not require a tracrRNA to be directed to the target site; crRNA alone is sufficient for Cas12a. The gRNA guides the active CRISPR nuclease complex to the target site, where the CRISPR nuclease can cleave the target site.

[0075] In some embodiments, the present disclosure provides at least one guide RNA. In some embodiments, the present disclosure provides at least two guide RNAs. In some embodiments, the present disclosure provides at least three guide RNAs. In some embodiments, the present disclosure provides a nucleic acid sequence encoding at least one guide RNA. In some embodiments, the nucleic acid sequence encoding the guide RNA is operably linked to a promoter. In some embodiments, the guide RNA is a single guide RNA. In some embodiments, the guide RNA comprises a tracrRNA. In some embodiments, the guide RNA comprises a crRNA.

[0076] In some embodiments, the present disclosure provides a first guide RNA and a second guide RNA. In some embodiments, the first guide RNA and the second guide RNA are each operably linked to a promoter. In some embodiments, the first guide RNA is operably linked to a first promoter, and the second guide RNA is operably linked to a second promoter. In some embodiments, the first guide RNA and the second guide RNA are operably linked to the same promoter. In some embodiments, the first guide RNA and the second guide RNA are operably linked to different promoters.

[0077] In certain embodiments, the guide RNA can hybridize to a target site for a guided nuclease or to a nucleic acid sequence located within 50 nucleotides of a target site for a guided nuclease.

[0078] In some embodiments, the guide RNA can hybridize with a target site for an inducible nuclease. In some embodiments, the guide RNA can hybridize with a target site for an inducible nuclease in a recombinant DNA construct provided herein but not in a plant genome. In some embodiments, the guide RNA can hybridize with a target site for an inducible nuclease in a plant genome but not in a recombinant DNA construct provided herein. In some embodiments, the guide RNA can hybridize with a first target site for an inducible nuclease in a recombinant DNA construct and a second target site for an inducible nuclease in the genome of a plant, wherein the first and second target sites comprise the same sequence.

[0079] In some embodiments, the guide RNA comprises at least 10 nucleotides. In some embodiments, the guide RNA comprises at least 11 nucleotides. In some embodiments, the guide RNA comprises at least 12 nucleotides. In some embodiments, the guide RNA comprises at least 13 nucleotides. In some embodiments, the guide RNA comprises at least 14 nucleotides. In some embodiments, the guide RNA comprises at least 15 nucleotides. In some embodiments, the guide RNA comprises at least 16 nucleotides. In some embodiments, the guide RNA comprises at least 17 nucleotides. In some embodiments, the guide RNA comprises at least 18 nucleotides. In some embodiments, the guide RNA comprises at least 19 nucleotides. In some embodiments, the guide RNA comprises at least 20 nucleotides. In some embodiments, the guide RNA comprises at least 21 nucleotides. In some embodiments, the guide RNA comprises at least 22 nucleotides. In some embodiments, the guide RNA comprises at least 23 nucleotides. In some embodiments, the guide RNA comprises at least 24 nucleotides. In some embodiments, the guide RNA comprises at least 25 nucleotides. In some embodiments, the guide RNA comprises at least 26 nucleotides. In some embodiments, the guide RNA comprises at least 27 nucleotides. In some embodiments, the guide RNA comprises at least 28 nucleotides. In some embodiments, the guide RNA comprises at least 30 nucleotides. In some embodiments, the guide RNA comprises at least 35 nucleotides. In some embodiments, the guide RNA comprises at least 40 nucleotides. In some embodiments, the guide RNA comprises at least 45 nucleotides. In some embodiments, the guide RNA comprises at least 50 nucleotides. In some embodiments, the guide RNA comprises at least 75 nucleotides. In some embodiments, the guide RNA comprises at least 100 nucleotides. In some embodiments, the guide RNA comprises at least 125 nucleotides.

[0080] In some embodiments, the guide RNA comprises 10 to 150 nucleotides. In some embodiments, the guide RNA comprises 10 to 125 nucleotides. In some embodiments, the guide RNA comprises 10 to 100 nucleotides. In some embodiments, the guide RNA comprises 10 to 75 nucleotides. In some embodiments, the guide RNA comprises 10 to 50 nucleotides. In some embodiments, the guide RNA comprises 10 to 40 nucleotides. In some embodiments, the guide RNA comprises 10 to 30 nucleotides. In some embodiments, the guide RNA comprises 10 to 20 nucleotides. In some embodiments, the guide RNA comprises 16 to 28 nucleotides. In some embodiments, the guide RNA comprises 16 to 25 nucleotides. In some embodiments, the guide RNA comprises 16 to 20 nucleotides.

[0081] In some embodiments, the target site for the inducible nuclease is 100% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 99% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 98% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 97% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 96% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 95% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 94% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 93% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 92% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 91% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 90% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 85% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 80% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 75% complementary to the guide RNA. In some embodiments, the target site for the inducible nuclease is 70% complementary to the guide RNA.

[0082] When an RNA-guided CRISPR nuclease and a guide RNA form a complex, the entire system is referred to as a "ribonucleoprotein." In some embodiments, the present disclosure provides a ribonucleoprotein.

[0083] A prerequisite for cleavage of a target site by a CRISPR ribonucleoprotein is the presence of a conserved protospacer adjacent motif (PAM) near the target site. Depending on the CRISPR nuclease, cleavage can occur within a certain number of nucleotides from the PAM site (e.g., between 18 and 23 nucleotides for Cas12a). A PAM site is only required for type I and type II CRISPR-associated proteins, and different CRISPR endonucleases recognize different PAM sites. Without limitation, Cas12a can recognize at least the following PAM sites: TTTN and YTN, and CasX can recognize at least the following PAM sites: TTCN, TTCA, and TTC (where T is thymine; C is cytosine; A is adenine; Y is thymine or cytosine; and N is thymine, cytosine, guanine, or adenine). In some embodiments, the target site for an inducible nuclease contains a PAM site.

[0084] In some embodiments, the target site for the inducible nuclease comprises at least one PAM site. In some embodiments, the target site for the inducible nuclease is adjacent to a nucleic acid sequence comprising at least one PAM site. In some embodiments, the target site for the inducible nuclease is within 5 nucleotides of at least one PAM site. In further embodiments, the target site for the inducible nuclease is within 10 nucleotides of at least one PAM site. In some embodiments, the target site for the inducible nuclease is within 15 nucleotides of at least one PAM site. In some embodiments, the target site for the inducible nuclease is within 20 nucleotides of at least one PAM site. In some embodiments, the target site for the inducible nuclease is within 25 nucleotides of at least one PAM site. In some embodiments, the target site for the inducible nuclease is within 30 nucleotides of at least one PAM site.

[0085] Cas12a (also known as Cpf1) is an RNA-guided nuclease of the class II, type V CRISPR / Cas system. Cas12a nuclease produces a staggered cut when cleaving a target nucleic acid molecule.

[0086] In some embodiments, the RNA-guided nuclease is a Cas12a nuclease. In some embodiments, the Cas12a nuclease is a Lachnospiraceae bacterial Cas12a (LbCas12a) nuclease. In some embodiments, the Cas12a nuclease is an Acidaminococcus sp. Cas12a (AsCas12a) nuclease. In some embodiments, the Cas12a nuclease provided herein is a Francisella novicida Cas12a (FnCas12a) nuclease. In some embodiments, the Cas12a nuclease or a nucleic acid encoding the Cas12a nuclease is selected from the group consisting of Streptococcus, Campylobacter, Nitratifractor, Staphylococcus, Parvibaculum, Roseburia, Neisseria, Gluconacetobacter, Azospirillum, Sphaerochaeta, Lactobacillus, Eubacterium, Corynebacterium, and the like. bacter, Carnobacterium, Rhodobacter, Listeria, Paludibacter, Clostridium, Lachnospiraceae, Clostridiaridium, Leptotrichia, Francisella, Legionella, Alicyclobacillus, Methanomethyophilus, Porphyromonas, Prevotella, Bacteroidetes,The bacterium is derived from a bacterial genus selected from the group consisting of Helcococcus, Letospira, Desulfovibrio, Desulfonatronum, Opitutaceae, Tuberibacillus, Bacillus, Brevibacilus, Methylobacterium, Acidaminococcus, Peregrinibacteria, Butyrivibrio, Parcubacteria, Smithella, Candidatus, Moraxella, and Leptospira.

[0087] In some embodiments, the RNA-guided nuclease is a Cas9 nuclease. In some embodiments, the RNA-guided nuclease is a CasX nuclease. In some embodiments, the RNA-guided nuclease is a CasY nuclease. In some embodiments, the RNA-guided nuclease is a Cas12a, Cas9, CasX, CasY, C2c2, Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas10, Csy1, Csy2, Csy3, Cse1, Cse2, Csc1, Csc2, Csa5, Csn2, C sm1, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, and Csf4.

[0088] After an integration event, the junction between the original chromosomal sequence and the integrated sequence was observed to contain one or more base pairs that were not uniquely assignable to the chromosomal or integrated sequence origin. It was hypothesized that these short (generally, but not always, six base pairs or less) microhomologies may be responsible for the efficiency of integration. See Figure 14.

[0089] Sequence origin ambiguity can arise through at least three mechanisms: (a) blunt-end ligation of small pieces resulting in ambiguous regions (e.g., artificial microhomology); (b) annealing and ligation of "sticky ends," analogous to in vitro restriction enzyme-mediated subcloning, where 5'- or 3'-overhanging single-stranded DNA regions anneal perfectly (e.g., full microhomology); and (c) ligation of partial chewback 5'- or 3'-single-stranded ends, resulting in one or more base pairs at the ends of the strands, followed by hypothetical filling and ligation of base pairs to complete the insertion (e.g., partial microhomology). See Figure 15. See also Example 5.

[0090] Enzymes such as Cas12a and CasX have different cleavage patterns compared to Cas9. Cas9 cleaves both strands at the same position, leaving blunt ends. Cas12a cleaves a target nucleic acid molecule, creating a staggered cut and resulting in an overhang on each cleaved strand. Cas12a cleaves in the 23-nt target region immediately preceding the PAM site. When Cas12a cleaves, it cleaves after position 19 (counting from the PAM) on one strand (also called the non-target strand) and after position 23 on the opposite strand (also called the target strand), generating a 4-nt 5' overhang on each strand (see Figure 16 and Zetsche et al., 2015, Cell, 163:759-771). For target sites containing a PAM (e.g., target sites cleaved by RNA-guided nucleases), nucleotide positions are counted from the PAM, and the first nucleotide after the PAM is considered position 1. For nucleases that cleave sites without PAM, nucleotide positions are counted backwards from the cleavage site on the target strand from 5' to 3', with the nucleotide closest to the cleavage site considered to be position 23.

[0091] It should also be noted that various versions of Cas12a variants can cleave with overhangs of different lengths—for example, some Cas12a variants are known to cleave after position 18, thus generating a 5-bp overhang (see Zetsche et al., 2015, Cell, 163:759-771). CasX also generates staggered ends at the target site. For example, DpbCasX generates products with approximately 10-nucleotide staggered ends due to cleavage 12-14 nucleotides after the PAM on the non-target strand and 22-25 nucleotides after the PAM on the target strand (see Liu et al., 2019, Nature, 566(7743):28-223).

[0092] As used herein, "target strand" refers to the DNA strand of the target site that binds to the guide RNA. The target strand is complementary to the "non-target strand" that does not bind to the guide RNA. Both the target strand and the non-target strand can be cleaved by RNA-guided nucleases.

[0093] For purposes of this disclosure, a 5' overhang in the target strand containing a PAM site is designated "A." A 5' overhang in the non-target strand that does not contain a PAM site is designated A' (see Figure 16). A' is the reverse complement of A and, theoretically, can perfectly reanneal with the A overhang. In some embodiments, A' comprises a 10-nucleotide overhang. In some embodiments, A' comprises a 9-nucleotide overhang. In some embodiments, A' comprises an 8-nucleotide overhang. In some embodiments, A' comprises a 7-nucleotide overhang. In some embodiments, A' comprises a 6-nucleotide overhang. In some embodiments, A' comprises a 5-nucleotide overhang. In some embodiments, A' comprises a 4-nucleotide overhang. In some embodiments, A' comprises a 3-nucleotide overhang. In some embodiments, A' comprises a 2-nucleotide overhang. In some embodiments, A' comprises a 1-nucleotide overhang.

[0094] In some embodiments, the non-target strand comprises a 10-nucleotide overhang. In some embodiments, the non-target strand comprises a 9-nucleotide overhang. In some embodiments, the non-target strand comprises an 8-nucleotide overhang. In some embodiments, the non-target strand comprises a 7-nucleotide overhang. In some embodiments, the non-target strand comprises a 6-nucleotide overhang. In some embodiments, the non-target strand comprises a 5-nucleotide overhang. In some embodiments, the non-target strand comprises a 4-nucleotide overhang. In some embodiments, the non-target strand comprises a 3-nucleotide overhang. In some embodiments, the non-target strand comprises a 2-nucleotide overhang. In some embodiments, the non-target strand comprises a 1-nucleotide overhang.

[0095] In some embodiments, the target strand comprises a 10-nucleotide overhang. In some embodiments, the target strand comprises a 9-nucleotide overhang. In some embodiments, the target strand comprises an 8-nucleotide overhang. In some embodiments, the target strand comprises a 7-nucleotide overhang. In some embodiments, the target strand comprises a 6-nucleotide overhang. In some embodiments, the target strand comprises a 5-nucleotide overhang. In some embodiments, the target strand comprises a 4-nucleotide overhang. In some embodiments, the target strand comprises a 3-nucleotide overhang. In some embodiments, the target strand comprises a 2-nucleotide overhang. In some embodiments, the target strand comprises a 1-nucleotide overhang.

[0096] In some embodiments, the overhang of the target strand comprises at least one nucleotide complementary to the genomic target site sequence. In some embodiments, the overhang of the target strand comprises at least two nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang of the target strand comprises at least three nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang of the target strand comprises at least four nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang of the target strand comprises at least five nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang of the target strand comprises at least six nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang of the target strand comprises at least seven nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang of the target strand comprises at least eight nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang of the target strand comprises at least nine nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang of the target strand comprises at least ten nucleotides complementary to the genomic target site sequence.

[0097] In some embodiments, the overhang on the non-target strand comprises at least 1 nucleotide complementary to the genomic target site sequence. In some embodiments, the overhang on the non-target strand comprises at least 2 nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang on the non-target strand comprises at least 3 nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang on the non-target strand comprises at least 4 nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang on the non-target strand comprises at least 5 nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang on the non-target strand comprises at least 6 nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang on the non-target strand comprises at least 7 nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang on the non-target strand comprises at least 8 nucleotides complementary to the genomic target site sequence. In some embodiments, the overhang on the non-target strand comprises at least 9 nucleotides complementary to the genomic target site sequence. In certain embodiments, the overhang on the non-target strand comprises at least 10 nucleotides complementary to the genomic target site sequence.

[0098] In some embodiments, the inducible nuclease can cleave a genomic target site. In some embodiments, the present disclosure provides a method comprising introducing any of the recombinant DNA constructs provided herein into a cell, wherein the inducible nuclease cleaves the target site for the inducible nuclease and the genomic target site, and the sequence of interest is inserted into the genomic target site.

[0099] In some embodiments, the sequence of nucleotides 20-23 of the target strand within the target site for the inducible nuclease is the reverse complement of the sequence of nucleotides 20-23 of the target strand within the genomic target site. In some embodiments, the sequence of nucleotides 1-19 of the target strand within the target site for the inducible nuclease is identical to the sequence of nucleotides 1-19 of the target strand within the genomic target site. In some embodiments, the sequence of nucleotides 1-19 of the target strand within the target site for the inducible nuclease is not identical to the sequence of nucleotides 1-19 of the target strand within the genomic target site. In some embodiments, the sequence of nucleotides 1-19 of the target strand within the target site for the inducible nuclease is the reverse complement of the sequence of nucleotides 1-19 of the target strand within the genomic target site.

[0100] In certain embodiments, the present disclosure provides an engineered double-stranded donor DNA molecule comprising one or more target sites for an inducible nuclease flanking at least one sequence of interest, wherein the sequence of nucleotides 20-23 of the target strand within the one or more target sites for the inducible nuclease is the reverse complement of the sequence of nucleotides 20-23 of the target strand within the genomic target site. In certain embodiments, the sequence of nucleotides 1-19 of the target strand within the one or more target sites for the inducible nuclease is identical to the sequence of nucleotides 1-19 of the target strand within the genomic target site. In certain embodiments, the sequence of nucleotides 1-19 of the target strand within the one or more target sites for the inducible nuclease is not identical to the sequence of nucleotides 1-19 of the target strand within the genomic target site. In some embodiments, the sequence of nucleotides 1-19 of the target strand within one or more target sites for an inducible nuclease is the reverse complement of the sequence of nucleotides 1-19 of the target strand within a genomic target site. In some embodiments, the double-stranded donor DNA molecule comprises two or more target sites for an inducible nuclease, the double-stranded donor DNA molecule comprising at least one target site for an inducible nuclease located 5' to at least one sequence of interest and at least one target site for an inducible nuclease located 3' to at least one sequence of interest. In some embodiments, the double-stranded donor DNA molecule comprises at least two genes of interest.

[0101] In certain embodiments, the present disclosure provides a method for introducing a double-stranded donor DNA molecule into a cell.

[0102] In some embodiments, the inducible nuclease generates a 4-nucleotide overhang after cleaving the recombinant nucleic acid construct at or near the target site for the inducible nuclease, ie, the inducible nuclease generates a 4-nucleotide overhang after cleaving the target site for the inducible nuclease in the plant genome or a site within 50 nucleotides of the target site in the plant genome.

[0103] In some embodiments, the inducible nuclease is a zinc finger nuclease (ZFN). ZFN is a synthetic protein consisting of an engineered zinc finger DNA binding domain fused to the cleavage domain of FokI restriction nuclease. Due to the modification of the zinc finger DNA binding domain, ZFN can be designed to cleave almost any length of double-stranded DNA. ZFN forms a dimer from a monomer composed of a non-specific DNA cleavage domain of FokI nuclease fused to a zinc finger array that is engineered to bind to the target DNA sequence.

[0104] The DNA-binding domain of a ZFN typically consists of an array of three to four zinc fingers. The amino acids at positions -1, +2, +3, and +6 relative to the start of the zinc finger ∞-helix, which contribute to site-specific binding to target DNA, can be altered and customized to fit specific target sequences. Other amino acids form a consensus backbone to generate ZFNs with different sequence specificities. Rules for selecting target sequences for ZFNs are known in the art.

[0105] The FokI nuclease domain requires dimerization to cleave DNA; therefore, two ZFNs with their C-terminal regions must bind to opposite DNA strands at the cleavage site (separated by 5–7 nucleotides). ZFN monomers can cleave a target site when the two ZF binding sites are palindromic. As used herein, the term ZFN is broad and includes monomeric ZFNs that can cleave double-stranded DNA without assistance from another ZFN. The term ZFN is also used to refer to one or both members of a pair of ZFNs engineered to work together to cleave DNA at the same site.

[0106] Without being limited by any scientific theory, customized ZFNs can theoretically be constructed to target almost any gene sequence because the DNA-binding specificity of zinc finger domains can, in principle, be re-engineered using one of a variety of methods. Publicly available methods for engineering zinc finger domains include Context-dependent Assembly (CoDA), Oligomerized Pool Engineering (OPEN), and Modular Assembly.

[0107] In some embodiments, the inducible nuclease is a meganuclease. Meganucleases, commonly identified in microorganisms, are unique enzymes with high activity and long recognition sequences (>14 nt) that result in site-specific digestion of target DNA. Engineered versions of naturally occurring meganucleases typically have extended DNA recognition sequences (e.g., from 14 nt to 40 nt). Engineering meganucleases can be more difficult than engineering ZFNs and TALENs because the DNA recognition and cleavage functions of meganucleases are intertwined in a single domain. Using specialized methods of mutagenesis and high-throughput screening, novel meganuclease variants that recognize unique sequences and have improved nuclease activity were created.

[0108] In some embodiments, the inducible nuclease is a transcription activator-like effector nuclease (TALEN). In some embodiments, the inducible nuclease is a transcription activator-like effector-like (TALEN-like) protein.

[0109] TALENs are artificial restriction enzymes created by fusing a transcription activator-like effector (TALE) DNA-binding domain to a FokI nuclease domain. When each member of a TALEN pair binds to a DNA site flanking the target site, the FokI monomer dimerizes, causing a double-stranded DNA break at the target site. In addition to the wild-type FokI cleavage domain, variants of the FokI cleavage domain with mutations have been designed to improve cleavage specificity and activity. The FokI domain functions as a dimer, requiring two constructs with unique DNA-binding domains for the target genome site with appropriate orientation and spacing. The number of amino acid residues between the TALEN DNA-binding domain and the FokI cleavage domain, as well as the number of bases between the two individual TALEN binding sites, are both parameters for achieving high levels of activity.

[0110] TALENs are artificial restriction enzymes created by fusing a transcription activator-like effector (TALE) DNA-binding domain to a nuclease domain. In one embodiment, the nuclease is selected from the group consisting of PvuII, MutH, TevI, and FokI, AlwI, MlyI, SbfI, SdaI, StsI, CleDORF, Clo051, and Pept071. When each member of a TALEN pair binds to a DNA site flanking the target site, the FokI monomer dimerizes and causes a double-stranded DNA break at the target site.

[0111] As used herein, the term TALEN includes a monomeric TALEN that can cleave double-stranded DNA without the assistance of another TALEN. The term TALEN is also used to refer to one or both members of a pair of TALENs that work together to cleave DNA at the same site.

[0112] Transcription activator-like effectors (TALEs) can be engineered to bind virtually any DNA sequence. TALE proteins are DNA-binding domains derived from various plant bacterial pathogens of the genus Xanthomonas. Xanthomonas pathogens secrete TALEs into host plant cells during infection. TALEs translocate to the nucleus, where they recognize and bind to specific DNA sequences in the promoter regions of specific genes in the host genome, resulting in modulation of gene expression. TALEs have a central DNA-binding domain composed of 13 to 28 repeating monomers of 33 to 34 amino acids. The amino acids in each monomer are highly conserved, except for hypervariable amino acid residues at positions 12 and 13. The two variable amino acids are called repeating variable dimers (RVDs). The amino acid pairs NI, NG, HD, and NN of the RVD preferentially recognize adenine, thymine, cytosine, and guanine / adenine, respectively, and the modulation of the RVD can recognize consecutive DNA bases. This simple relationship between amino acid sequence and DNA recognition has made it possible to engineer specific DNA-binding domains by selecting a combination of repeat segments containing appropriate RVDs. As used herein, "TALE binding site" (TBS) refers to a specific DNA sequence that recognizes and binds to the TALE DNA-binding domain of a TALE protein.

[0113] In addition to the wild-type FokI cleavage domain, variants of the FokI cleavage domain with mutations have been designed to improve cleavage specificity and activity. The FokI domain functions as a dimer, requiring two constructs with unique DNA-binding domains for the target genome site with appropriate orientation and spacing. The number of amino acid residues between the TALEN DNA-binding domain and the FokI cleavage domain, and the number of bases between two individual TALEN binding sites, are both parameters for achieving high levels of activity. PvuII, MutH, and TevI cleavage domains are useful alternatives to FokI and FokI variants for use with TALEs. PvuII functions as a highly specific cleavage domain when coupled to a TALE (see Yank et al. 2013, PLoS One. 8: e82539). MutH can introduce strand-specific nicks into DNA (see Gabsalilow et al. 2013, Nucleic Acids Research. 41: e83). TevI introduces a double-strand break in DNA at the targeted site (see Beurdeley et al., 2013. Nature Communications. 4: 1762).

[0114] The relationship between the amino acid sequence of the TALE binding domain and DNA recognition allows for proteins to be defined. Software programs such as DNA Works can be used to design TALE constructs. Other methods for designing TALE constructs are known to those skilled in the art. See Doyle et al., Nucleic Acids Research (2012) 40: W117-122; Cermak et al., Nucleic Acids Research (2011). 39: e82; and tale-nt.cac.cornell.edu / about.

[0115] As used herein, "sequence of interest" refers to the polynucleotide sequence that is to be integrated into the genome target sequence. In some embodiments, the sequence of interest is exogenous to the plant genome into which it is integrated. In some embodiments, the sequence of interest is endogenous to the plant genome into which it is integrated.

[0116] In some embodiments, the present disclosure provides a gene of interest. As used herein, a gene of interest refers to a polynucleotide sequence capable of producing a functional unit (such as, but not limited to, a protein or a non-coding RNA molecule). In some embodiments, the present disclosure provides a gene of interest that encodes a protein that confers an agronomic benefit to a plant (e.g., insect resistance, herbicide resistance, disease resistance, drought resistance, nitrogen use efficiency, protein expression, etc.). In some embodiments, the present disclosure provides at least one gene of interest. In some embodiments, the present disclosure provides at least two genes of interest. In some embodiments, the present disclosure provides at least three genes of interest.

[0117] In some embodiments, the recombinant nucleic acid construct comprises at least one sequence of interest for integration into a selected target site in the plant genome, hi some embodiments, the recombinant nucleic acid construct comprises at least two sequences of interest for integration into a selected target site in the plant genome.

[0118] The sequence of interest may comprise one or more of a promoter, an enhancer sequence, a leader sequence, a transcription initiation site, a protein-coding sequence, a transcription termination site, a polyadenylation site, one or more exons, one or more introns, a 5'-UTR, a 3'-UTR, a recombinase binding site, a gene of interest, or any combination thereof. In one embodiment, the sequence of interest encodes a non-coding RNA molecule or a precursor thereof. In certain embodiments, the sequence of interest encodes a protein. In one embodiment, the sequence of interest comprises an expression cassette. In one embodiment, the sequence of interest comprises a target site for an inducible nuclease.

[0119] Non-limiting examples of non-coding RNA molecules include microRNAs (miRNAs), miRN precursors (pre-miRNAs), small interfering RNAs (siRNAs), small RNAs (18-26 nucleotides in length) and their encoding precursors, heterochromatin siRNAs (hc-siRNAs), Piwi interfering RNAs (piRNAs), hairpin double-stranded RNAs (hairpin dsRNAs), trans-acting siRNAs (ta-siRNAs), naturally occurring antisense siRNAs (nat-siRNAs), CRISPR RNAs (crRNAs), tracer RNAs (tracrRNAs), guide RNAs (gRNAs), and single guide RNAs (sgRNAs). In some embodiments, the non-coding RNA molecule comprises a miRNA. In some embodiments, the non-coding RNA molecule comprises a siRNA. In some embodiments, the non-coding RNA molecule comprises a ta-siRNA. In some embodiments, the non-coding RNA molecule is selected from the group consisting of a miRNA, an siRNA, and a ta-siRNA.

[0120] In some embodiments, the gene of interest is operably linked to a promoter. In some embodiments, the gene of interest is operably linked to its native promoter. In some embodiments, the gene of interest is operably linked to a heterologous promoter. As used herein, the term "heterologous" with respect to a promoter refers to a promoter sequence that has a different origin from its associated transcribable DNA sequence, coding sequence, or gene (or transgene) and / or does not naturally occur in the plant species being transformed. More broadly, the term "heterologous" can refer to the combination of two or more DNA molecules or sequences, such as a promoter and an associated transcribable DNA sequence, coding sequence, or gene, when such a combination is artificial and not normally found in nature. In contrast, the term "native" with respect to a promoter refers to a promoter sequence that has the same origin as its associated transcribable DNA sequence and occurs naturally with the associated transcribable DNA sequence.

[0121] As used herein, the term "promoter" refers to a DNA sequence that contains an RNA polymerase binding site, a transcription initiation site, and / or a TATA box and supports or facilitates the transcription and expression of an associated transcribable polynucleotide sequence and / or gene (or transgene). Promoters can be synthetically generated, modified, or derived from known or naturally occurring promoter sequences or other promoter sequences. Promoters can also include chimeric promoters, which comprise a combination of two or more heterologous sequences. Thus, promoters of the present application can include variants of promoter sequences that are similar in composition but not identical to other promoter sequences known or provided herein. Promoters can be classified according to various criteria related to the pattern of expression of the associated coding sequence or transcribable sequence or gene (including transgene) operably linked to the promoter, e.g., constitutive, developmental, tissue-specific, cell cycle-specific, inducible, etc.

[0122] In some embodiments, the recombinant nucleic acid construct comprises at least one promoter. In some embodiments, the recombinant nucleic acid construct comprises at least two promoters. In some embodiments, the recombinant nucleic acid construct comprises at least three promoters. In some embodiments, the recombinant nucleic acid construct comprises at least four promoters. In some embodiments, the recombinant nucleic acid construct comprises at least five promoters.

[0123] As used herein, "operably linked" refers to a functional linkage between two or more elements. For example, an operable linkage between a gene of interest and a regulatory sequence (e.g., a promoter) is a functional linkage that allows expression of the gene of interest. Operable linked elements can be contiguous or non-contiguous.

[0124] A promoter that drives expression in all or most tissues of a plant is called a "constitutive" promoter. A promoter that drives expression during a specific period or stage of development is called a "developmental" promoter. An "inducible" promoter is a promoter that initiates transcription in response to an environmental stimulus, such as heat, cold, drought, light, or other stimuli such as wounding or chemical application. Promoters can also be classified in terms of their origin, e.g., heterologous, homologous, chimeric, synthetic, etc.

[0125] In some embodiments, the promoters provided herein are constitutive promoters. In yet other embodiments, the promoters provided herein are inducible promoters. In some embodiments, the promoters provided herein are tissue-specific promoters. In some embodiments, the promoters provided herein are selected from the group consisting of constitutive promoters, inducible promoters, and tissue-specific promoters.

[0126] RNA polymerase III (Pol III) promoters can be used to drive expression of non-protein-coding RNA molecules. In some embodiments, the promoters provided herein are Pol III promoters. In some embodiments, the Pol III promoters provided herein are operably linked to a nucleic acid molecule encoding a non-protein-coding RNA. In yet other embodiments, the Pol III promoters provided herein are operably linked to a nucleic acid molecule encoding a single guide RNA. In further embodiments, the Pol III promoters provided herein are operably linked to a nucleic acid molecule encoding a CRISPR RNA (crRNA). In some embodiments, the Pol III promoters provided herein are operably linked to a nucleic acid molecule encoding a tracer RNA (tracrRNA).

[0127] Non-limiting examples of Pol III promoters include the U6 promoter, the H1 promoter, the 5S promoter, the adenovirus 2 (Ad2) VAI promoter, the tRNA promoter, and the 7SK promoter. See, e.g., Schramm and Hernandez, 2002, Genes & Development, 16:2593-2620, which is incorporated herein by reference in its entirety. In some embodiments, the Pol III promoter provided herein is selected from the group consisting of the U6 promoter, the H1 promoter, the 5S promoter, the adenovirus 2 (Ad2) VAI promoter, the tRNA promoter, and the 7SK promoter. In some embodiments, the guide RNA provided herein is operably linked to a promoter selected from the group consisting of the U6 promoter, the H1 promoter, the 5S promoter, the adenovirus 2 (Ad2) VAI promoter, the tRNA promoter, and the 7SK promoter. In some embodiments, the single guide RNA provided herein is operably linked to a promoter selected from the group consisting of a U6 promoter, an H1 promoter, a 5S promoter, an adenovirus 2 (Ad2) VAI promoter, a tRNA promoter, and a 7SK promoter. In some embodiments, the CRISPR RNA provided herein is operably linked to a promoter selected from the group consisting of a U6 promoter, an H1 promoter, a 5S promoter, an adenovirus 2 (Ad2) VAI promoter, a tRNA promoter, and a 7SK promoter. In some embodiments, the tracer RNA provided herein is operably linked to a promoter selected from the group consisting of a U6 promoter, an H1 promoter, a 5S promoter, an adenovirus 2 (Ad2) VAI promoter, a tRNA promoter, and a 7SK promoter.

[0128] In some embodiments, the promoter provided herein is a dahlia mosaic virus (DaMV) promoter. In some embodiments, the promoter provided herein is a U6 promoter. In some embodiments, the promoter provided herein is an actin promoter. In some embodiments, the promoter provided herein is a cauliflower mosaic virus (CaMV) 35S promoter. In some embodiments, the promoter provided herein is a ubiquitin promoter.

[0129] In certain embodiments, the constitutive promoter is selected from the group consisting of a CaMV 35S promoter, an actin promoter, and a ubiquitin promoter.

[0130] Examples describing promoters that can be used herein include, but are not limited to, U.S. Pat. No. 6,437,217 (maize RS81 promoter), U.S. Pat. No. 5,641,876 (rice actin promoter), U.S. Pat. No. 6,426,446 (maize RS324 promoter), U.S. Pat. No. 6,429,362 (maize PR-1 promoter), U.S. Pat. No. 6,232,526 (maize A3 promoter), U.S. Pat. No. 6,177,611 (constitutive maize promoters), U.S. Pat. Nos. 5,322,938, 5,352,605, 5,359,142, and 5,530,196 (35S promoter), U.S. Pat. No. 6,433,252 (maize L3 oleosin promoter), U.S. Pat. No. 6,429,357 (rice actin 2 promoter and rice actin 2 intron), U.S. Pat. No. 5,837,848 (root-specific promoter), U.S. Pat. No. 6,294,714 (light-inducible promoter), U.S. Pat. No. 6,140,078 (salt-inducible promoter), U.S. Pat. No. 6,252,138 (pathogen-inducible promoter), U.S. Pat. No. 6,175,060 (phosphorus deficiency-inducible promoter), U.S. Pat. No. 6,635,806 (gamma-coixin promoter), and U.S. Patent Application No. 09 / 757,089 (maize chloroplast aldolase promoter).Additional promoters that may find use include the nopaline synthase (NOS) promoter (Ebert et al., 1987), the octopine synthase (OCS) promoter (as carried in the tumor-inducing plasmid of Agrobacterium tumefaciens), caulimovirus promoters, such as the cauliflower mosaic virus (CaMV) 19S promoter (Lawton et al., Plant Molecular Biology (1987) 9:315-324), the CaMV 35S promoter (Odell et al., Nature (1985) 313:810-812), the figwort mosaic virus 35S promoter (U.S. Patent Nos. 6,051,753; 5,378,619), the sucrose synthase promoter (Yang and Russell, Proceedings of the National Academy of Sciences, USA (1990) 87: 4144-4148), the R gene complex promoter (Chandler et al., Plant Cell (1989) 1:1175-1183), and the chlorophyll a / b binding protein gene promoter, PC1SV (U.S. Patent No. 5,850,019), and the AGRtu.nos (GenBank accession V00087; Depicker et al., Journal of Molecular and Applied Genetics (1982) 1:561-573; Bevan et al., 1983) promoter.

[0131] Promoter hybrids can also be used and constructed to enhance transcriptional activity (see U.S. Pat. No. 5,106,739) or to combine desired transcriptional activity, inducibility, and tissue or developmental specificity. Promoters that function in plants include, but are not limited to, inducible, viral, synthetic, constitutive, temporally regulated, spatially regulated, and spatiotemporally regulated promoters. Other tissue-enhanced, tissue-specific, or developmentally regulated promoters are known in the art and are contemplated as having utility in practicing the present disclosure.

[0132] A selectable marker can be used to aid in the selection of transformed cells or tissues due to the presence of a selective agent, such as an antibiotic or herbicide, where the selectable marker gene confers resistance or tolerance to the selective agent. Thus, the selective agent can bias or support the survival, development, growth, proliferation, etc., of transformed cells expressing the selectable marker gene. Commonly used selectable marker genes include, but are not limited to, those that confer resistance or tolerance to antibiotics, such as kanamycin and paromomycin (nptII), hygromycin B (aph IV), streptomycin or spectinomycin (aadA), and gentamicin (aac3 and aacC4), or those that confer resistance or tolerance to herbicides, such as glufosinate (bar or pat), dicamba (DMO), and glyphosate (aroA or Cp4-EPSPS). Selectable marker genes that provide the ability to visually screen for transformation can also be used. Non-limiting examples include genes that express luciferase or green fluorescent protein (GFP), or beta-glucuronidase or the uidA gene (GUS), for which various chromogenic substrates are known. In one embodiment, a nucleic acid molecule provided herein comprises a selectable marker gene selected from the group consisting of nptII, aph IV, aadA, aac3, aacC4, bar, pat, DMO, EPSPS, aroA, luciferase, GFP, and GUS.

[0133] In some embodiments, the present disclosure provides a selectable marker gene. In some embodiments, the present disclosure provides a sequence encoding a selectable marker gene. In some embodiments, the present disclosure provides at least one selectable marker gene. In some embodiments, the present disclosure provides at least two selectable marker genes. In some embodiments, the present disclosure provides at least three selectable marker genes. In some embodiments, a recombinant nucleic acid construct comprises at least one selectable marker gene.

[0134] In some embodiments, the sequence encoding the selectable marker gene is operably linked to a promoter. In some embodiments, the sequence encoding the selectable marker gene comprises at least one intron. In some embodiments, the sequence encoding the selectable marker gene comprises at least two introns. In some embodiments, the intron comprises a single intron sequence divided into two or more intron sequences.

[0135] In some embodiments, the sequence encoding the selectable marker gene comprises a protein-coding sequence. In some embodiments, the sequence encoding at least one selectable marker comprises (a) a promoter; (b) at least one intron; and (c) a protein-coding sequence. In some embodiments, the recombinant nucleic acid construct comprises at least one sequence encoding at least one selectable marker gene. In some embodiments, the recombinant nucleic acid construct comprises at least two sequences encoding at least two selectable marker genes.

[0136] In certain aspects, the present disclosure provides compositions and methods for utilizing replicase proteins and long intergenic region (LIR) sequences from geminiviruses and nanoviruses to promote the integration of a DNA sequence of interest at a selected location in a plant genome. The Geminiviridae and Nanoviridae families are families of plant-infecting viruses with circular ssDNA genomes. Geminiviruses and nanoviruses typically replicate via a rolling circle mechanism. The replication initiator protein / replicase (Rep) recognizes a domain in the large intergenic region (LIR) and nicks the DNA at a conserved 9-nt site found in the hairpin structure of the LIR, promoting rolling circle replication. As a result, a newly synthesized ssDNA replicon is formed, which is then converted back to a dsDNA replicon. As used herein, "long intergenic region," "long intergenic repeat," or "LIR" refers to a long intergenic region containing a replicase / rep binding site that can mediate excision and replication by the viral replicase / Rep protein. LIRs contain conserved or partially conserved sites that recognize, bind to, and nick the replicase protein of its cognate virus during rolling circle replication. In some embodiments, the LIR is derived from a geminivirus. In some embodiments, the LIR is derived from soybean chlorotic spot virus. In some embodiments, the LIR is derived from a nanovirus. In some embodiments, the LIR is derived from faba bean necrotic yellow virus. As used herein, "replicase" or "replication inhibitor protein" or "viral replicase" or "Rep" refers to a protein that can replicate DNA associated with its cognate LIR. In some embodiments, the replicase is derived from a geminivirus. In some embodiments, the replicase is derived from soybean spotted wilt virus. In some embodiments, the replicase is derived from a nanovirus.In some embodiments, the replicase is derived from the broad bean necrotic yellows virus.

[0137] Some embodiments relate to methods and compositions for providing multiple copies of a DNA sequence of interest for targeted integration at selected sites in a plant genome by flanking the DNA sequence of interest with LIR sequences and providing a cognate replicase. In some embodiments, the DNA sequence of interest comprises a target site for an inducible nuclease (e.g., a TALEN target site, a ZFN target site, a Cas12a target site, a Cas9 target site, an Isce1 target site, etc.). In some embodiments, the DNA sequence of interest comprises one or more homology arms. In some embodiments, the DNA sequence of interest and flanking LIR sequences are provided to a plant cell in a T-DNA via Agrobacterium-mediated transformation. In some embodiments, the T-DNA further comprises one or more of an expression cassette encoding a replicase, an expression cassette encoding an inducible nuclease, an expression cassette encoding a selectable marker, or an expression cassette encoding one or more guide RNAs, wherein one or more of the expression cassettes are not provided between the LIR sequences. In some embodiments, the inducible nuclease cleaves a target site in the plant genome. In some embodiments, the inducible nuclease cleaves a target site in the plant genome and a target site in the DNA sequence of interest. In some embodiments, the T-DNA comprises one or more expression cassettes encoding a guide RNA that targets a site in the plant genome and a guide RNA that targets a site in the DNA sequence of interest. In some embodiments, a second T-DNA is provided that further comprises an expression cassette encoding a replicase.

[0138] The Nanoviridae family includes two genera: Babuvirus and Nanovirus. All viruses in this family are hybrid, meaning they maintain their genomes in multiple segments of circular, positive-sense ssDNA. Examples of the nanovirus genus include broad bean necrotic yellows virus (FBNYV), subterranean clover stunt virus (SCSV), milk vetch dwarf virus (MDV), banana bunchy top virus (BBTV), abaca bunchy top virus (ABTV), coconut foliar decay virus (CFDV), cardamom bushy dwarf virus (CBDV), black medic leaf roll virus (BMLRV), and pea yellow stunt virus (PYSV).

[0139] The Geminiviridae family is a large family that includes 14 genera, including Becurtovirus, Begomovirus, Capulavirus, Curtovirus, Eragrovirus, Grablovirus, Mastrevirus, Topocuvirus, and Turncurtovirus. Examples of geminiviruses include Maize streak virus (MSV), Soybean spotted wilt virus (SCSV), Cabbage leaf curl virus (CLCV / CaLCuV), Tomato golden mosaic virus (TGMV), Bean yellow dwarf virus (BeYDV; also known as Chickpea chlorotic dwarf virus), African cassava mosaic virus, Wheat dwarf virus (WDV), Miscanthus streak mastrevirus, Tobacco yellow dwarf virus, Tomato yellow leaf curl virus (TyLCV), and Bean golden mosaic virus (TGMV). virus, beet curly top virus, and tomato pseudo-curly top virus. In some embodiments, the sequences of interest provided herein are integrated into the plant genome. In some embodiments, the integration of the sequences of interest into the plant genome comprises site-specific integration.

[0140] As used herein, "site-specific integration" refers to all or a portion of a desired sequence (e.g., a sequence of interest) being inserted or integrated at a desired site or locus (e.g., a target sequence) within a plant genome. In certain embodiments, the recombinant nucleic acid construct further comprises a first homology arm (HR1) and a second homology arm (HR2). As used herein, "homology arm" refers to a sequence that is essentially identical to or essentially complementary to a sequence at or near a target site within the genome of a plant. In some embodiments, the homology arms are at least about 2, at least about 3, at least about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least about 9, at least about 10, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, at least about 60, at least about 65, at least about 70, at least about 75, at least about 80, at least about 85, at least about 90, at least about 95, at least about 100, at least about 150, at least about 200, at least about 250, at least about 300, at least about 350, at least about 400, at least about 450, at least about 500, or more nucleotides. The homology arms can direct integration of a sequence of interest into a target site in the genome of a plant via homologous recombination, wherein the homology arms are essentially identical to or essentially complementary to a sequence at or near the target site in the genome of a plant. In some embodiments, the sequence of interest comprises a homology arm at its 5' end and a homology arm at its 3' end. In some embodiments, a target site for an inducible nuclease is located between the homology arms. In some embodiments, the sequence of interest comprises a target site for an inducible nuclease located outside the sequences flanking the homology arms. In some embodiments, the recombinant nucleic acid construct comprises a target sequence complementary to a spacer between two homology arms.

[0141] In some embodiments, the methods provided herein involve the site-specific integration of a sequence of interest (e.g., a gene of interest, an expression element, a sequence encoding a non-coding RNA, a recombination site, a target site for an inducible nuclease, a transcription termination site, etc.) into the genome of a plant cell.

[0142] For site-specific integration, a double-strand break (DSB) or nick can first be created at the target site for the inducible nuclease in the plant genome via an inducible nuclease or ribonucleoprotein (e.g., a Cas12a system, a Cas9 system, etc.) provided herein. In the presence of a sequence of interest, the DSB or nick can then be repaired by homologous recombination (HR) between the homologous arms of the sequence of interest and the target sequence, or by non-homologous end joining (NHEJ), or by microhomology-mediated end joining (MMEJ), resulting in site-specific integration of all or part of the sequence of interest into the target site for the inducible nuclease in the plant genome, creating a targeted insertion event at the site of the DSB or nick.

[0143] In some embodiments, site-specific integration involves the use of an NHEJ repair mechanism endogenous to the cell. In some embodiments, site-specific integration involves the use of an HR repair mechanism endogenous to the cell. In some embodiments, site-specific integration involves the use of an MMEJ repair mechanism endogenous to the cell.

[0144] In some embodiments, the present disclosure provides a plant comprising a recombinant DNA construct provided herein. In some embodiments, the present disclosure provides a plant cell comprising a recombinant DNA construct provided herein. In some embodiments, the present disclosure provides a plant comprising an integrated sequence of interest provided by the method provided herein. In some embodiments, the present disclosure provides a plant cell comprising an integrated sequence of interest provided by the method provided herein.

[0145] Any plant or plant cell can be used with the methods and compositions provided herein. In some embodiments, the plant is an angiosperm. In some embodiments, the plant is a gymnosperm. In some embodiments, the plant is a monocotyledonous plant. In some embodiments, the plant is a dicotyledonous plant. In some embodiments, the plant cell is an angiosperm cell. In some embodiments, the plant cell is a gymnosperm cell. In some embodiments, the plant cell is a monocotyledonous plant cell. In some embodiments, the plant cell is a dicotyledonous plant cell.

[0146] In some embodiments, the plant or plant cell is from the family Alliaceae, Anacardiaceae, Apiaceae, Arecaceae, Asteraceae, Brassicaceae, Caesalpiniaceae, Cucurbitaceae, Ericaceae, Fabaceae, Juglandaceae, A. The plant or plant cell is a plant or plant cell of a family selected from the group consisting of Malvaceae, Mimosaceae, Moraceae, Musaceae, Orchidaceae, Papilionaceae, Pinaceae, Poaceae, Rosaceae, Rutaceae, Rubiaceae, and Solanaceae.

[0147] In some embodiments, the plant is selected from the group consisting of a corn plant, a rice plant, a sorghum plant, a wheat plant, an alfalfa plant, a barley plant, a millet plant, a rye plant, a sugarcane plant, a cotton plant, a soybean plant, a canola plant, a tomato plant, an onion plant, a cucumber plant, an Arabidopsis plant, and a potato plant. In some embodiments, the plant cell is selected from the group consisting of a corn cell, a rice cell, a sorghum cell, a wheat cell, an alfalfa cell, a barley cell, a millet cell, a rye cell, a sugarcane cell, a cotton cell, a soybean cell, a canola cell, a tomato cell, an onion cell, a cucumber cell, an Arabidopsis cell, and a potato cell.

[0148] In some embodiments, the plant is a corn plant. In some embodiments, the plant is a soybean plant. In some embodiments, the plant cell is a corn cell. In some embodiments, the plant cell is a soybean cell.

[0149] In some embodiments, the recombinant nucleic acid constructs provided herein are provided to or transformed into plant cells. Agrobacterium-mediated transformation is fully described in U.S. Patent Nos. 5,159,135; 5,824,877; 5,591,616; 6,384,301; 5,750,871; 5,463,174; and 5,188,958, all of which are incorporated herein by reference.

[0150] Any suitable plant cell can be used for Agrobacterium-mediated transformation. Recipient plant cells or explant targets for transformation include, but are not limited to, seed cells, fruit cells, leaf cells, cotyledon cells, hypocotyl cells, meristem cells, embryo cells, endosperm cells, root cells, shoot cells, stem cells, sheath cells, flower cells, inflorescence cells, stem cells, pedicel cells, style cells, stigma cells, receptacle cells, petal cells, sepal cells, pollen cells, anther cells, filament cells, ovary cells, ovule cells, pericarp cells, phloem cells, bud cells, or vascular tissue cells. In some embodiments, the present disclosure provides plant chloroplasts. In further embodiments, the present disclosure provides epidermal cells, guard cells, trichome cells, root hair cells, storage root cells, or tuber cells. In some embodiments, the present disclosure provides protoplasts. In some embodiments, the present disclosure provides plant callus cells.

[0151] Any cell from which a fertile plant can be regenerated is contemplated as a useful recipient cell for practicing the present disclosure. Callus can be initiated from a variety of tissue sources, including, but not limited to, immature embryos or parts of embryos, seedling apical meristematic points, microspores, etc. These cells capable of growing as callus can serve as recipient cells for transformation. Actual transformation methods and materials for producing the transgenic plants of the present disclosure (e.g., various media and recipient target cells, transformation of immature embryos, and subsequent regeneration of fertile transgenic plants) are disclosed, for example, in U.S. Patent Nos. 6,194,636 and 6,232,526, and U.S. Patent Application Publication No. 2004 / 0216189, all of which are incorporated herein by reference.

[0152] Transformed explants, cells, or tissues may be subjected to additional culture steps known in the art, such as callus induction, selection, regeneration, etc. Transformed cells, tissues, or explants containing recombinant DNA inserts can be grown, developed, or regenerated into transgenic plants in culture, plugs, or soil according to methods known in the art. In one aspect, the present disclosure provides plant cells that are not propagation material and do not mediate natural plant reproduction. In some embodiments, the present disclosure also provides plant cells that are propagation material and mediate natural plant reproduction. In some embodiments, the present disclosure provides plant cells that cannot sustain themselves through photosynthesis. In some embodiments, the present disclosure provides somatic plant cells. Somatic cells, in contrast to germline cells, do not mediate plant reproduction. In one embodiment, the present disclosure provides non-propagating plant cells.

[0153] The use of the terms "polynucleotide" or "nucleic acid molecule" is not intended to limit the present disclosure to polynucleotides comprising deoxyribonucleic acid (DNA). For example, ribonucleic acid (RNA) molecules are also contemplated. Those skilled in the art will recognize that polynucleotides and nucleic acid molecules can comprise deoxyribonucleotides, ribonucleotides, or combinations of ribonucleotides and deoxyribonucleotides. Such deoxyribonucleotides and ribonucleotides include both naturally occurring molecules and synthetic analogues. Polynucleotides of the present disclosure also encompass all forms of sequences, including, but not limited to, single-stranded forms, double-stranded forms, hairpins, stem and loop structures, etc. In some embodiments, the nucleic acid molecules provided herein are DNA molecules. In some embodiments, the nucleic acid molecules provided herein are RNA molecules. In some embodiments, the nucleic acid molecules provided herein are single-stranded. In some embodiments, the nucleic acid molecules provided herein are double-stranded.

[0154] Nucleic acid molecules have a directionality or "orientation" due to the nature of their structure. Typically, a single DNA or RNA strand has a 5' end where a phosphate group is attached to the 5' carbon of the ribose ring, and a 3' end where a hydroxyl group is attached to the 3' carbon of the ribose ring. Nucleic acids are transcribed in a forward, or 5' to 3', orientation. When two sequences are said to be in the "same orientation," they are both in the 5' to 3' orientation or they are both in the 3' to 5' orientation within the nucleic acid strand. If one sequence is in the 5' to 3' orientation, the sequence in the 3' to 5' orientation is said to be in the opposite orientation.

[0155] Nucleic acids can be isolated using techniques routine in the art. For example, nucleic acids can be isolated using any method, including, but not limited to, recombinant nucleic acid technology and / or polymerase chain reaction (PCR). General PCR techniques are described, for example, in PCR Primer: A Laboratory Manual, edited by Dieffenbach & Dveksler, Cold Spring Harbor Laboratory Press, 1995. Recombinant nucleic acid techniques include, for example, restriction enzyme digestion and ligation, which can be used to isolate nucleic acids. Isolated nucleic acids can also be chemically synthesized, either as a single nucleic acid molecule or as a series of oligonucleotides. Polypeptides can be purified from natural sources (e.g., biological samples) by known methods, such as DEAE ion exchange, gel filtration, and hydroxyapatite chromatography. Polypeptides can also be purified, for example, by expressing nucleic acids in expression vectors. In addition, purified polypeptides can be obtained by chemical synthesis. The degree of purity of a polypeptide can be measured using any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.

[0156] Without limitation, nucleic acids can be detected using hybridization. Hybridization between nucleic acids is discussed in detail in Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).

[0157] The term "percent identity" or "percent identity," when used herein with respect to two or more nucleotide or protein sequences, is calculated by (i) comparing two optimally aligned sequences (nucleotide or protein) over a comparison window, (ii) determining the number of positions where the same nucleic acid base (for nucleotide sequences) or amino acid residue (for proteins) occurs in both sequences to obtain the number of matched positions, (iii) dividing the number of matched positions by the total number of positions in the comparison window, and then (iv) multiplying this quotient by 100% to obtain the percent identity. When "percent identity" is calculated with respect to a reference sequence where a specific comparison window is not specified, the percent identity is determined by dividing the number of matched positions over the region of alignment by the total length of the reference sequence. Thus, for purposes of this application, when two sequences (query and subject) are optimally aligned (allowing for gaps in their alignment), the "percent identity" for a query sequence is equal to the number of identical positions between the two sequences divided by the total number of positions in the query sequence over its length (or comparison window), then multiplied by 100%. When percentages of sequence identity are used with respect to proteins, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions, in which an amino acid residue is substituted with another having similar chemical properties (e.g., charge or hydrophobicity), thus not altering the functional properties of the molecule. When sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Sequences that differ by such conservative substitutions are said to have "sequence similarity" or "similarity."

[0158] The terms "percent sequence complementarity" or "percent complementarity," as used herein in reference to two nucleotide sequences, are similar to the concept of percent identity, but refer to the percentage of nucleotides in a query sequence that optimally base-pair or hybridize with the nucleotides of a subject sequence when the query and subject sequences are linearly arranged and optimally base-paired, without secondary folding structures such as loops, stems, or hairpins. Such percent complementarity can be between two DNA strands, two RNA strands, or between a DNA strand and an RNA strand. "Percent complementarity" can be calculated by (i) optimally base-pairing or hybridizing two nucleotide sequences in a linear, fully extended configuration (i.e., without folding or secondary structure) over the comparison window, (ii) determining the number of base-pairing positions between the two sequences over the comparison window to obtain the number of complementary positions, (iii) dividing the number of complementary positions by the total number of positions in the comparison window, and (iv) multiplying this quotient by 100% to obtain the percent complementarity of the two sequences. Optimal base pairing of two sequences can be determined based on known pairing of nucleotide bases such as GC, AT, and AU by hydrogen bonding. When "percent complementarity" is calculated with respect to a reference sequence without specifying a specific comparison window, the percent identity is determined by dividing the number of complementary positions between two linear sequences by the total length of the reference sequence. Thus, for the purposes of this application, when two sequences (query and subject) are optimally base-paired (allowing for mismatched or non-base-paired nucleotides), the "percent complementarity" of a query sequence is equal to the number of base-paired positions between the two sequences divided by the total number of positions in the query sequence over its length, then multiplied by 100%.

[0159] As used herein, an "essentially identical" sequence refers to a sequence that is at least 95% identical to a second sequence. As used herein, an "essentially complementary" sequence refers to a sequence that is at least 95% complementary to a second sequence.

[0160] For optimal alignment of sequences to calculate their percent identity, various pairwise or multiple sequence alignment algorithms and programs are known in the art, such as ClustalW or Basic Local Alignment Search Tool (BLAST®), which can be used to compare sequence identity or similarity between two or more nucleotide or protein sequences. Although other alignment and comparison methods are known in the art, the alignment and percent identity between two sequences (including the percent identity ranges described above) can be determined by the ClustalW algorithm, see, for example, Chenna R. et al., "Multiple sequence alignment with the Clustal series of programs," Nucleic Acids Research 31: 3497-3500 (2003); Thompson JD et al., "Clustal W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice," Nucleic Acids Research 22: 4673-4680 (1994); Larkin MA et al., "Clustal W and Clustal X version 2.0," Bioinformatics 23: 2947-48 (2007); and Altschul, S. F., Gish, W., Miller, See W., Myers, EW and Lipman, DJ (1990) "Basic local alignment search tool." J. Mol. Biol. 215:403-410 (1990).

[0161] As used herein, a first nucleic acid molecule (e.g., a guide RNA) can "hybridize" with a second nucleic acid molecule (e.g., a target site for an inducible nuclease) through non-covalent interactions (e.g., Watson-Crick base pairing) in a sequence-specific antiparallel manner (i.e., the nucleic acid specifically binds to a complementary nucleic acid) under appropriate in vitro and / or in vivo conditions of temperature and solution ionic strength. As known in the art, standard Watson-Crick base pairing includes adenine pairing with thymine, adenine pairing with uracil, and guanine (G) pairing with cytosine (C) [DNA, RNA]. In addition, it is also known in the art that guanine bases pair with uracil for hybridization between two RNA molecules (e.g., dsRNA). For example, G / U base pairing is partially responsible for the degeneracy (i.e., redundancy) of the genetic code in the context of base pairing of tRNA anticodons with codons in mRNA. In the context of the present disclosure, a guanine in the protein-binding segment (dsRNA duplex) of a subject DNA-targeting RNA molecule is considered complementary to a uracil, and vice versa. Therefore, if a G / U base pair can be created in the protein-binding segment (dsRNA duplex) of a subject DNA-targeting RNA molecule at a given nucleotide position, that position is not considered non-complementary, but instead is considered complementary.

[0162] Hybridization and washing conditions are well known and are exemplified in Sambrook, J., Fritsch, E. F., and Maniatis, T., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor (1989), especially Chapter 11 and Table 11.1 therein; and Sambrook, J., and Russell, W., Molecular Cloning: A Laboratory Manual, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor (2001). Conditions of temperature and ionic strength determine the "stringency" of hybridization.

[0163] Hybridization requires that two nucleic acids contain complementary sequences, although mismatches between bases are possible. Conditions suitable for hybridization between two nucleic acids depend on the length of the nucleic acids and the degree of complementarity, variables well known in the art. The greater the degree of complementarity between two nucleotide sequences, the greater the melting temperature (Tm) value for hybrids of nucleic acids having those sequences. For hybridization between nucleic acids with short stretches of complementarity (e.g., complementarity over 35 nucleotides or less), the location of mismatches becomes important (see Sambrook et al.). Typically, the length for a hybridizable nucleic acid is at least 10 nucleotides. Exemplary minimum lengths for a hybridizable nucleic acid are at least 15 nucleotides; at least 18 nucleotides; at least 20 nucleotides; at least 22 nucleotides; at least 25 nucleotides; and at least 30 nucleotides. Furthermore, those skilled in the art will recognize that the temperature and salt concentration of the wash solution can be adjusted as necessary depending on factors such as the length of the complementary region and the degree of complementarity.

[0164] It is understood in the art that the sequence of a polynucleotide does not need to be 100% complementary to the sequence of its target nucleic acid to be specifically hybridizable or hybridizable. Also, a polynucleotide can hybridize across one or more segments such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure or a hairpin structure). For example, an antisense nucleic acid in which 18 of 20 nucleotides of an antisense compound are complementary to a target region and therefore specifically hybridizes represents 90 percent complementarity. In this example, the remaining non-complementary nucleotides can be clustered or interspersed with complementary nucleotides and do not need to be adjacent to each other or to complementary nucleotides. The percent complementarity between particular stretches of nucleic acid sequences within a nucleic acid can be routinely determined using the BLAST® program (Basic Local Alignment Search Tool) and PowerBLAST program known in the art (see Altschul et al., J. Mol. Biol., 1990, 215, 403-410; Zhang and Madden, Genome Res., 1997, 7, 649-656), or by using the Gap program (Wisconsin Sequence Analysis package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using the algorithm of Smith and Waterman (Adv. Appl. Math., 1981, 2, 482-489), using default settings.

[0165] Various species exhibit specific biases toward certain codons for specific amino acids. Codon bias (differences in codon usage among organisms) often correlates with the efficiency of messenger RNA (mRNA) translation, which in turn is thought to depend, among other things, on the nature of the codon being translated and the availability of specific transfer RNA (tRNA) molecules. The prevalence of selected tRNAs in a cell generally reflects the codons most frequently used in peptide synthesis. Therefore, genes can be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are readily available, for example, in the "Codon Usage Database," available at www.kazusa.or.jp / codon, and these tables can be adapted in a number of ways. See Nakamura et al., 2000, Nucl. Acids Res. 28:292. Computer algorithms are also available for optimizing codons for a particular sequence for expression in a particular host cell, for example, Gene Forge (Aptagen; Jacobus, PA).

[0166] As used herein, "codon optimization" or "codon optimized" refers to the process of modifying a nucleic acid sequence for enhanced expression in a host cell of interest by replacing at least one codon of the sequence (e.g., at least 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons) with a codon that is more frequently or most frequently used in the genes of the host cell, while maintaining the original amino acid sequence (e.g., introducing silent mutations).

[0167] In some embodiments, one or more codons (e.g., 1, 2, 3, 4, 5, 10, 15, 20, 25, 50, or more codons, or all codons) in the recombinase-encoding sequence, inducible nuclease, sequence of interest, or selectable marker gene correspond to the most frequently used codon for a particular amino acid. For codon usage in plants, see Campbell and Gowri, 1990, Plant Physiol., 92:1-11; and Murray et al., 1989, Nucleic Acids Res., 17:477-98, each of which is incorporated by reference in its entirety.

[0168] In some embodiments, the nucleic acid sequence encoding the inducible nuclease is codon-optimized for plant cells. In some embodiments, the nucleic acid sequence encoding the inducible nuclease is codon-optimized for monocotyledonous plant cells. In some embodiments, the nucleic acid sequence encoding the inducible nuclease is codon-optimized for dicotyledonous plant cells. In some embodiments, the nucleic acid sequence encoding the inducible nuclease is codon-optimized for corn cells. In some embodiments, the nucleic acid sequence encoding the inducible nuclease is codon-optimized for soybean cells.

[0169] In some embodiments, the nucleic acid sequence encoding the recombinase is codon-optimized for plant cells. In some embodiments, the nucleic acid sequence encoding the recombinase is codon-optimized for monocotyledonous plant cells. In some embodiments, the nucleic acid sequence encoding the recombinase is codon-optimized for dicotyledonous plant cells. In some embodiments, the nucleic acid sequence encoding the recombinase is codon-optimized for corn cells. In some embodiments, the nucleic acid sequence encoding the recombinase is codon-optimized for soybean cells.

[0170] In some embodiments, the nucleic acid sequence is codon-optimized for a plant cell. In some embodiments, the nucleic acid sequence encoding the inducible nuclease is codon-optimized for a monocotyledonous plant cell. In some embodiments, the nucleic acid sequence encoding the inducible nuclease is codon-optimized for a dicotyledonous plant cell. In some embodiments, the nucleic acid sequence encoding the inducible nuclease is codon-optimized for a corn cell. In some embodiments, the nucleic acid sequence encoding the inducible nuclease is codon-optimized for a soybean cell. In some embodiments, the nucleic acid sequence encoding the protein that confers an agronomic benefit is codon-optimized for a monocotyledonous plant cell. In some embodiments, the nucleic acid sequence encoding the protein that confers an agronomic benefit is codon-optimized for a dicotyledonous plant cell. In some embodiments, the nucleic acid sequence encoding the protein that confers an agronomic benefit is codon-optimized for a corn cell. In some embodiments, the nucleic acid sequence encoding the protein that confers an agronomic benefit is codon-optimized for a soybean cell.

[0171] In some embodiments, the nucleic acid sequence encoding the selectable marker gene is codon-optimized for plant cells. In some embodiments, the nucleic acid sequence encoding the selectable marker gene is codon-optimized for monocotyledonous plant cells. In some embodiments, the nucleic acid sequence encoding the selectable marker gene is codon-optimized for dicotyledonous plant cells. In some embodiments, the nucleic acid sequence encoding the selectable marker gene is codon-optimized for corn cells. In some embodiments, the nucleic acid sequence encoding the selectable marker gene is codon-optimized for soybean cells.

[0172] Having now generally described the disclosure, it will be more readily understood by reference to the following examples, which are provided for illustrative purposes and are not intended as limitations of the disclosure, unless otherwise specified. [Example]

[0173] Example 1 Donor vector design and testing This example describes the design and testing of a donor vector containing a selectable marker gene cassette, a CRISPR RNA-guided LbCas12a endonuclease expression system, and a gene of interest (GOI) flanked by nuclease target sites for site-specific integration (SDI) at the GmTS1 target site in the soybean genome.

[0174] The Agrobacterium T-DNA vector configuration includes right border (RB) DNA sequences (SEQ ID NO: 1) and left border (LB) DNA sequences (SEQ ID NO: 2) flanking the five expression cassettes shown in FIG. 1.

[0175] Cassette 1 is an expression cassette for the selectable marker gene aadA. The expression cassette (SEQ ID NO:3) contains the promoter (SEQ ID NO:4), leader (SEQ ID NO:5), and intron sequences (SEQ ID NO:6), all derived from the Arabidopsis thaliana actin 7 gene, operably linked 5' to a nucleotide sequence encoding the Arabidopsis thaliana EPSPS transit peptide (SEQ ID NO:7), followed by the E. coli aadA reporter gene (SEQ ID NO:8) and a transcription termination sequence (SEQ ID NO:9) derived from the Agrobacterium nos gene.

[0176] Cassette 2 is an expression cassette containing the gene of interest (GOI 1) under the control of a non-constitutive promoter.

[0177] Cassette 3 is an expression cassette encoding the CRISPR / Cas12a nuclease (SEQ ID NO: 33) derived from the Lachnospiraceae bacterium ND2006 (LbCas12a).

[0178] Cassette 4 is an expression cassette encoding the LbCas12a gRNA, containing a soybean U6 promoter (SEQ ID NO: 34) operably linked to DNA encoding the LbCas12a guide RNA. The guide RNA contains a 21-nucleotide crRNA (SEQ ID NO: 24) of a generic guide RNA scaffold sequence compatible with the LbCas12a enzyme, along with a unique 23-nucleotide spacer complementary to the GmTS1 target site in the soybean genome.

[0179] Cassette 5 is an expression cassette encoding a second gene of interest (GOI 2) under the control of a constitutive promoter. Cassette 5 is flanked by the GmTS1 target site, as shown in Figure 1. A T-DNA construct designed to integrate GOI 1 into a specific chromosomal target site (GmTS1) after LbCas12a simultaneously cleaves GOI 1 and the chromosomal target site flanking the target site, but the selectable marker gene, along with other accessory nuclease gene cassettes, is integrated into a separate chromosomal location. This arrangement allows the integrated GOI 1 to be separated from the marker gene in progeny.

[0180] Embryos excised from A3555 soybean plants are co-cultured with Agrobacterium containing the vector described above. Transformed plants are selected in spectinomycin. Leaf samples from regenerated plantlets are harvested after 10 weeks, and genomic DNA is extracted from shoot tissue.

[0181] To identify plants with site-specific integration of GOI1 at the GmTS1 target site, a flanking PCR assay similar to that described in WO2019 / 084148 (incorporated herein by reference in its entirety) is performed using a pair of PCR primers flanking the intended GmTS1 target site. Genomic DNA from positive flanking PCR results, indicating a putative SDI event, is sequenced.

[0182] As mentioned above, GOI 1 is expected to be excised from the T-DNA either before or after integration of the T-DNA into the chromosome and then inserted independently from the rest of the T-DNA at the specific target site in the chromosome cleaved by the LbCas12a-gRNA.

[0183] Of 1,000 plantlets, 67 events with positive flanking PCR products were sequenced, among which a total of 10 SDI events were identified. Eight single-copy SDI events were identified at the GmTS1 chromosomal target site, and these events were subjected to detailed sequence analysis.

[0184] Of the eight events analyzed, all contained T-DNA inserted at the target site by nonhomologous end joining (NHEJ). No SDI events with single-copy insertions and the expected transgene / genome junction with an intact cassette were identified. Interestingly, six of the eight events analyzed showed the unexpected junction of RB and LB sequences, as illustrated in Figure 1B. This unexpected conformation could be explained by linearization of the circularized T-DNA by CRISPR nuclease cleavage at at least one of the two gRNA target sites, followed by integration of the linearized T-DNA by NHEJ at the GmTS1 target site in the chromosome.

[0185] Sixteen events in which the T-DNA had been randomly inserted at sites other than the GmTS1 target site were also analyzed using the same sequence analysis strategy. These 16 non-targeted events showed no evidence of de novo RB and LB junctions as observed in the precise events.

[0186] T-strand / T-DNA circularization in plants has been described previously (see Koukolikova-Nicola et al., 1985; Singer et al., 2012). Circularized T-DNA constructs were rescued from plant cells by Agrobacterium cocultivation. The junction sequence of the circular intermediate was confirmed to be present in the 25-nucleotide direct repeats typically found at the ends of the T-DNA region of the Ti plasmid (Koukolikova-Nicola et al., 1985). Evidence indicated that single-stranded T-DNA is converted to a double-stranded form prior to integration (Singer et al., 2012). It has been proposed that the ends of linear double-stranded T-DNA are recognized and repaired by the plant's double-strand break-repair machinery, leading to chromosomal integration, the formation of an extrachromosomal complex T-DNA structure that can then be integrated, or an extrachromosomal circular form of T-DNA (Singer et al., 2012). Circularized T-DNA was speculated to be a dead end in plant cells compared to linear double-stranded T-DNA (Singer et al., 2012).

[0187] Without being bound by any scientific theory, in a subset of T-DNA molecules, the dsDNA T-DNA spontaneously circularizes, joining the RB end to the LB end, creating an imprecise junction that may involve truncation of both ends. LbCas12a-mediated cleavage of the circular T-DNA at at least one of the GmTS1 target sites linearizes it, creating a substrate for targeted insertion of the linearized T-DNA into a chromosomal target site cleaved by a gRNA-guided nuclease.

[0188] Example 2 Design and testing of T-DNA vectors This example describes the design and testing of a T-DNA vector containing a split marker cassette flanked by RB and LB and a single target site for the CRISPR LbCas12a nuclease system. This vector configuration is expected to enrich for targeted insertions in the soybean genome and result in the marker gene cassette being disrupted upon random T-DNA integration.

[0189] aadA selectable marker cassette: The aadA expression cassette (SEQ ID NO: 3) described in Example 1 (see FIG. 2) contains the promoter (P-ACT7) (SEQ ID NO: 4), leader (L-) (SEQ ID NO: 5), and intron sequence (I-Act7) (SEQ ID NO: 6), all derived from the Arabidopsis actin 7 gene, operably linked at the 5′ end to a nucleotide sequence encoding the Arabidopsis EPSPS transit peptide (CTP) (SEQ ID NO: 7), followed by the E. coli aadA reporter gene (aadA) (SEQ ID NO: 8) and a transcription termination sequence (SEQ ID NO: 9) derived from the Agrobacterium nos gene (T-nos). Position 270 within the actin 7 (Act7) intron sequence of the aadA cassette was selected as the split site. The 5′ portion of the aadA cassette (5′ marker cassette), including the promoter, leader, and first 270 nucleotides of the Act7 intron, is shown in SEQ ID NO: 10. The "3' marker cassette" (SEQ ID NO: 11) contains the 3' portion of the Act7 intron, the aadA coding sequence, and the nos transcription terminator.

[0190] RB and LB truncations: The vector described in Example 1 utilizes the 505-nucleotide octopine RB sequence (SEQ ID NO: 1) and the 442-nucleotide octopine LB sequence (SEQ ID NO: 2). To facilitate placement of border sequences within the intron and promote efficient intron splicing, the internal border sequences within the RB and / or LB are truncated (see Figure 3). The truncations are designed to reduce the border residue size after end joining inside the split intron. Two Agrobacterium T-DNA vectors were designed for this purpose and are described below.

[0191] Soybean split marker vector 1: The GmSMV1 T-DNA vector contains a deletion of the RB and LB internal border sequences (see Figure 3), resulting in 26-nucleotide border residues being retained within the reconstituted Act7 intron after T-DNA end joining. The sequence of the 181-nucleotide truncated LB sequence (tLB) is shown in SEQ ID NO: 12, and the 218-nucleotide truncated RB sequence (tLB) is shown in SEQ ID NO: 13. As shown in Figure 3, the 25-nucleotide essential core LB sequence (SEQ ID NO: 14) and essential core RB sequence (SEQ ID NO: 15) are retained in the truncated versions. The 5' marker cassette (SEQ ID NO: 10) was PCR amplified and fused 5' to tRB as shown in Figure 4. The 3' marker cassette (SEQ ID NO: 11) was PCR amplified and fused 3' to tRB as shown in Figure 4. In addition, the GmSMV1 vector contains the four functional cassettes present in the vector described in Example 1 (see Figure 4).

[0192] Cassette 1 is an expression cassette for a gene of interest (GOI 2) under the control of a non-constitutive promoter. Cassette 2 is an expression cassette for LbCas12a nuclease (SEQ ID NO: 33). Expression cassette 3 is an expression cassette for LbCas12a gRNA and contains a soybean U6 promoter (SEQ ID NO: 34) operably linked to a 21-nucleotide crRNA sequence and a unique 23-nucleotide spacer sequence complementary to the GmTS1 target site. Cassette 4 is an expression cassette encoding a second gene of interest (GOI 1) under the control of a constitutive promoter. The vector also contains a 27-nucleotide sequence encoding the GmTS1 target site located 3' to the GOI 2 cassette. Finally, the GOI 2 cassette with the GmTS1 target site is flanked by LoxP recombination sites (see US2020 / 0032289, incorporated herein by reference in its entirety).

[0193] Soybean split marker vector 2: GmSMV2 T-DNA vector has a similar design to GmSMV1 with four functional cassettes, a split marker, and tRB border sequences, but contains an intact longer LB sequence (see Figures 3 and 4), which results in the 265-nucleotide border residues being retained within the reconstituted Act7 intron after T-DNA end joining.

[0194] Plant transformation and SDI screening: Embryos excised from A3555 soybean plants were co-cultured with Agrobacterium containing either GmSMV1 or GmSMV2 as described above. A total of 48,000 explants were co-cultured with the two constructs and selected for shoot elongation on spectinomycin medium. Without being bound by any scientific theory, in the majority of explants, the linear T-DNA was randomly integrated into the DSB in the chromosome. Because the aadA marker cassette is not functional, these explants are not expected to survive on spectinomycin selection medium. In a subset of T-DNA molecules, the dsDNA T-DNA spontaneously circularized, joining the RB end to the LB end. Circularization reconstituted a spliceable intron (within the selection marker cassette) and resulted in a functional aadA expression cassette. This results in the recovery of plants in which the T-DNA has either progressed through the circularization pathway or ligated with other T-DNAs to form dimers with RB-LB junctions.

[0195] Spectinomycin-resistant shoots were transferred to soil plugs for rooting. DNA was extracted from leaf samples and used for copy number determination using a TaqMan™-based assay known in the art. To identify plants with site-specific integration of the T-DNA at the GmTS1 site, a flanking PCR assay similar to that described in WO 2019 / 084148 (incorporated herein in its entirety) was performed, using pairs of PCR primers flanking the intended GmTS1 target site. DNA from flanking PCR-positive putative targeting events was subjected to sequence analysis. A total of 336 samples (84 samples / plate) were collected and analyzed to identify targeting events (see Table 1). Of these, 50 events with low copy numbers (1-2 copies) from each construct with positive flanking PCR results for either flanking region were further advanced for genome sequencing and detailed integration analysis. The results are summarized in Table 1 and compared to events resulting from a control T-DNA vector containing an intact aadA selectable marker cassette as described in Example 1.

[0196] High-quality SDI events are defined as single-copy insertion of T-DNA at the targeting site with an intact cassette and the expected essential transgene / genome junction. The SDI percentage is defined as the ratio of high-quality SDI events to the sample. The percentage of high-quality SDI in two-copy events indicates that these plants have two copies of TDNA, with at least one TDNA being a high-quality SDI insertion. These plants require progeny segregation for single-copy commercial-quality SDI events.

[0197] [Table 1]

[0198] As shown in Table 1, a 10-fold increase in the rate of high-quality SDI event generation was observed for GmSMV1 compared to the control. A 7-fold increase was observed for GmSMV2 compared to the control. A 3% transformation frequency (TF) was observed in GmSMV1 coculture explants, compared to 1.58% TF from GmSMV2 coculture explants. This suggests, without being limited by any scientific theory, that the presence of longer LB residues within the Act7 intron in SMV2 may negatively affect efficient intron splicing and functionality.

[0199] Example 3 Design and testing of T-DNA vectors This example describes the design and testing of a T-DNA vector containing a split marker cassette flanked by RB and LB and target sites for the CRISPR LbCas12a nuclease system. This vector configuration is expected to enrich for targeted insertions in the maize ZmTS1 genomic region, resulting in a disrupted marker gene cassette upon random T-DNA integration.

[0200] CP4 selectable marker cassette: The functional CP4 expression cassette (SEQ ID NO:17) contains the rice actin 7 promoter (SEQ ID NO:18), leader (SEQ ID NO:19), and intron sequence (SEQ ID NO:20) operably linked at the 5' end to a nucleotide sequence encoding the Arabidopsis thaliana EPSPS transit peptide (SEQ ID NO:7), followed by the coding sequence for the Agrobacterium EPSPS-CP4 reporter gene (SEQ ID NO:21), which confers resistance to glyphosate, and the transcription termination sequence from the Agrobacterium nos gene (SEQ ID NO:9). Position 239 within the actin 1 intron sequence of the CP4 cassette was selected as the split site. The 5' end of the CP4 cassette (5' CP4 marker cassette), including the promoter, leader, and first 239 nucleotides of the actin 1 intron, is shown in SEQ ID NO:22. The 3' end of the "3' CP4 marker cassette," including the 239 nucleotides of the actin 1 intron, the CP4 coding sequence, and the nos transcription terminator, is shown in SEQ ID NO:23.

[0201] The maize split marker vector 1:ZmSMV1 T-DNA vector contains the tRB (SEQ ID NO: 13) and tLB (SEQ ID NO: 12) sequences, four functional cassettes, and a split CP4 marker cassette (see Figure 4). The 5' CP4 marker cassette (SEQ ID NO: 22) is located 5' to the tRB. The 3' CP4 marker cassette (SEQ ID NO: 23) is located 3' to the tLB. The vector also contained an expression cassette for a gene of interest (GOI 1) under the control of a non-constitutive promoter and an expression cassette for the LbCas12a nuclease (SEQ ID NO: 26). An expression cassette encoding an LbCas12a guide RNA containing a 21-nucleotide crRNA (SEQ ID NO: 24), a generic guide RNA scaffold sequence compatible with the LbCas12a enzyme, and a unique 23-nucleotide spacer complementary to the Zm7.1_TS1 target site was also provided. An expression cassette encoding a second gene of interest (GOI 2) under the control of a constitutive promoter was also provided. The vector also contained a 27-nucleotide sequence encoding a ZmTS1 target site located 3' to the GOI 2 cassette. Finally, the GOI 2 cassette with the ZmTS1 target site was flanked by LoxP recombination sites.

[0202] Example 4 Maize transformation Maize transformation, flank PCR, and SDI confirmation: Embryos of maize cultivar 01DKD2 were transformed with Agrobacterium containing the ZmSMV1 T-DNA vector described in Example 3 using methods known in the art. Stably transformed plants were selected against glyphosate. Leaf samples from regenerated plantlets were harvested after two weeks, and genomic DNA was extracted for copy number determination by a TaqMan™-based assay known in the art.

[0203] To identify plants with site-specific integration of the T-DNA at the ZmTS1 site, a flank PCR assay was performed using a pair of PCR primers flanking the intended target site. DNA from flank PCR-positive putative SDI events was subjected to sequence analysis. Events with low copy numbers (1-2 copies) and flank PCR-positive results for either flanking region were further advanced for genome sequencing and detailed integration analysis to identify the proportion of events and commercial-quality SDIs. As noted in Table 2, one SDI event was identified among the 84 samples analyzed.

[0204] [Table 2]

[0205] Example 5 Binary construct design This example describes the design of a binary construct with two gRNA expression cassettes provided on a T-DNA: one targeting a unique site in the T-DNA and a second targeting a unique site in the genome (see, e.g., Figure 5).

[0206] Cas12a cleaves in the 23-nt target region immediately preceding the PAM site. When Cas12a cleaves, it cleaves after position 19 on one strand (the "non-target strand") and after position 23 on the opposite strand (the "target strand"), generating a 4-nt 5' overhang on each strand (see, e.g., Figure 16). The 5' overhang on the end containing the PAM site and the 19-nt target site is marked with the letter A. The 5' overhang on the other fragment, which has only the 4-nt target site fragment and does not contain PAM, is represented as A'. A' is the reverse complement of A and, theoretically, can perfectly reanneal with the A overhang.

[0207] Observations from Examples 1 and 2 suggest that different LbCas12a targeting sites between the T-DNA and genome result in increased SDI efficiency. The vast majority of observed SDI events were in the "reverse" orientation, in which the orientation of the cleaved target site in the T-DNA insertion is opposite that of the cleaved target site on the genome. See, for example, Figure 17. As shown in Figure 17, at one end, an inverted pair of cleaved target sites (minus a certain amount of sequence chewback) is ligated (A to A ligation), while at the other end, the ligation is between the 4 bp 3' end of the inverted target region and some sequence chewback. See Figure 17; A' to A' ligation. The chewback observed in the A' to A' ligation for the inverted orientation event was significantly shorter than the chewback observed in all other sets of NHEJ ligations, which appeared to be of similar size. See Table 2. Without being limited by any scientific theory, this may initiate events with the SDI in the reverse orientation, thus avoiding exposure to Chewback.

[0208] The average sequence chewback is only 5.7 nucleotides for the A' end of chromosome 6 (CR06) and 1.8 nucleotides for the A' end of the T-DNA. Furthermore, the prevalence of ambiguous assignment is much greater than expected from random occurrence: 14 of 21 events (67%) exhibited this, and in 12 of those 14 events, the ambiguity was consistent with microhomology-mediated annealing of the 5' single-stranded end of the truncated T-DNA to the 5' single-stranded end of CR06. Only three events were observed to have slightly longer chewbacks of an additional two or three nucleotides. These observations are specific to events in the reverse (REV) orientation. Events in the forward (FWD) orientation had fewer (six in total) longer chewbacks.

[0209] [Table 3]

[0210] Taken together, these data provide evidence for two classes of events. Class I events, which are in the reverse (REV) orientation, are represented by short chewbacks at the A' / A' junction, a high occurrence of apparent microhomology (1-3 nt sequences at the junction due to either of the pre-attached pieces), and an enhanced frequency of occurrence. Class II events, represented by longer chewbacks, appear to have no preference for directionality (approximately equal numbers are present in both directions). The data also provide evidence suggesting that microhomology enhances the efficiency of precise insertion. While not wishing to be bound by a particular theory, it may be possible to maximize the efficiency of donor insertion by maximizing the likelihood of productive microhomology-assisted NHEJ while minimizing the occurrence of non-productive NHEJ (as detailed below). Microhomology-assisted NHEJ can occur when the chromosomal 5' overhang (A') and the T-DNA 5' overhang (A') (either full-length or partial chewback, respectively) have annealing base pairs at their ends that can then fill in to heal the junction. See Figure 15C. Without being bound by any theory, it may be possible to increase the efficiency of reverse-orientation Class 1 events by altering the T-strand target site to minimize the potential for microhomology due to the cleaved genomic target site.

[0211] To visualize this process, a chart of potential overlaps can be created to identify both the direct partners involved in the microhomology and the number of base pairs involved in the potential microhomology. See Figure 17. To maximize the potential for microhomology, it is preferable to alter at least the last four nucleotides (nt) of the target site on the T-DNA strand to their reverse complement (e.g., compare GmTS1 and GmTS1_4RC in Figure 18C). As shown in Figure 18D, A' / A' interactions between the cleaved genomic target site and the cleaved T-DNA target site slightly increase both the number of potential microhomology pairings as well as the bp length of these individual possibilities.

[0212] Two target sites within the soybean chromosome, 20.38.4 (SEQ ID NO: 27) and 05.37.8 (SEQ ID NO: 30), were identified, and gRNA spacer sequences were designed to target these sites (see Table 4). T-DNA target sites were designed to promote microhomology-assisted annealing with the respective genomic target sites (TS) (see rows 2, 3, 5, and 6 in Table 4). Constructs were designed to promote microhomology-assisted SDI augmentation in two different ways.

[0213] In the first design ("Design 1"), positions 1-19 are identical between the genomic and T-DNA target sites. However, positions 20-23 within the T-DNA target site are designed to be the reverse complement (RC) of positions 20-23 of the genomic target site. For example, compare rows 1 and 2, or rows 4 and 5 in Table 4. Because of the tendency for T-DNA to insert into chromosomes with the A' end of the truncated T-DNA pairing with the A' end of the truncated chromosome (and the A end of the truncated T-DNA pairing with the truncated A end), the strands involved in the initiation end are complementary (maximizing microhomology support) and have many opportunities to have shorter microhomologies, even with minor deletions of either strand.

[0214] In the second design ("Design 2"), the sequence of the T-DNA target site is completely unrelated to the genomic target site, except that, as in the previous design, positions 20-23 within the T-DNA target site are designed to be the reverse complement (RC) of positions 20-23 in the genomic target site. For example, compare lines 1 and 3, or lines 4 and 6 in Table 4. In cases where Design 1 results in a gRNA predicted to perform poorly or produce imprecise cleavage, Design 2 may cleave the circularized T-DNA more efficiently. Additionally, because the sequence on the second end does not form a short inverted repeat with the cleaved genomic copy of Target 1, this may result in increased efficiency if the absence of an inverted repeat increases the efficiency of healing at that end. Alternative lengths of the designed 3' inversion are also anticipated, ranging from 1 to 6 nucleotides, all of which are predicted to simply create opportunities for microhomology-assisted increases in integration rates.

[0215] [Table 4]

[0216] Six T-DNA constructs are generated, comprising, in 5' to 3' order: a truncated left border (tLB) sequence; a 3' marker cassette fragment (SEQ ID NO: 11); a promoter operably linked to a sequence encoding Cas12a; a promoter operably linked to a sequence encoding a guide RNA array comprising gRNA1 and gRNA2 (gRNA1 targets a native chromosomal target site, while gRNA2 targets a site in the T-DNA); a promoter operably linked to a sequence encoding gene of interest 2, a lox site, a promoter operably linked to a sequence encoding gene of interest 1, a target site recognized by Cas12a and gRNA2, a second lox site, a 5' marker cassette fragment (SEQ ID NO: 10); and a truncated right border (tRB) sequence. See Figure 5.

[0217] [Table 5]

[0218] The construct is introduced into plant cells via Agrobacterium-mediated transformation. A subset of the T-DNA is circularized, and the Cas12a-gRNA2 complex cleaves the circularized T-DNA, while the Cas12a-gRNA1 complex cleaves the genomic target site. Circularization and subsequent cleavage of the T-DNA allows for targeted integration of the linearized T-DNA into the genomic target site. Circularization and linearization also reconstitute a spliceable intron within the marker cassette, thus allowing the promoter to drive expression of a selectable marker gene, thus enabling selection of events that have undergone circularization and subsequent T-DNA integration. Flank PCR assays and genomic DNA sequencing are performed to identify plants with targeted integration events. The rate of targeted integration between the test and control vectors is analyzed to determine whether increased microhomology between the A' end of the Cas12a cleavage fragment in the T-DNA and the genomic target site results in increased efficiency of targeted integration.

[0219] Example 6 Improving SDI frequency by reducing vector backbone containing events Transgenic plants produced as described in Examples 1 and 2 were subjected to copy number and vector backbone analysis as shown in Table 6. The frequency of single copy events for both split marker T-DNA constructs is half that observed in the control T-DNA configuration. Furthermore, more than 75% of transgenic events from the two split marker T-DNA configurations (GmSMV1 and GmSMV2) had two or more copies of the transgene.

[0220] [Table 6]

[0221] These observations provide an opportunity to improve the frequency of targeted integration events by reducing or eliminating vector backbone-containing events. Two strategies are described to reduce the occurrence of backbone-containing events.

[0222] A) Split marker vector with a crtB cassette: It has previously been shown that expression of a non-lethal negative selection marker (e.g., the crtB gene) in a binary vector backbone can significantly reduce the frequency of backbone-containing events (see Ye et al., Transgenic Res. 17:827-38 (2008); and U.S. Pat. No. 7,575,917, both of which are incorporated by reference in their entireties). A modified SMV1 vector, GmSMV3, was designed in which an expression cassette containing the crtB gene (SEQ ID NO: 36) was inserted into the vector backbone. The GmSMV3 vector contained a T-DNA construct including, in 5' to 3' order, a truncated left border (tLB) sequence (SEQ ID NO: 12); a 3' marker cassette (SEQ ID NO: 11) in a forward orientation; an expression cassette for a gene of interest (GOI 2) under the control of a non-constitutive promoter; an expression cassette for a Cas12a nuclease-encoding sequence; an expression cassette for a Cas12a gRNA targeting the GmTS2 target site in the soybean genome; a first Lox site; an expression cassette for gene of interest 1 (GOI 1) under the control of a constitutive promoter; a 27-nucleotide sequence encoding the GmTS2 target site; a spacer sequence (SEQ ID NO: 16); a second Lox site; a 5' marker cassette (SEQ ID NO: 10) in a forward orientation; and a truncated right border (tRB) (SEQ ID NO: 13). The vector further contained an expression cassette for the crtB gene operably linked to the cauliflower mosaic virus 35S constitutive promoter located outside the T-DNA sequence. See Figure 12A. Two controls were generated for this experiment: Control 1 was a standard control vector containing a functional aadA marker cassette with a design similar to that described in Example 1. Control 2 was identical to the GmSMV3 vector but lacked the crtB expression cassette.

[0223] Embryos excised from A3555 soybean plants were co-cultured with Agrobacterium containing the GmSMV3 vector or a control vector, and transformed plants were selected for shoot elongation on spectinomycin medium. Spectinomycin-resistant shoots were transferred to soil plugs for rooting. DNA was extracted from leaf samples and used for copy number determination by a TaqMan™-based assay. A flanking PCR assay was used to identify plants with site-specific integration of the T-DNA at the GmTS2 site. DNA from flanking PCR-positive putative targeting events was further processed for genome sequencing to confirm SDI and analyze the presence of the vector backbone. The results are summarized in Tables 7 and 8.

[0224] [Table 7]

[0225] [Table 8]

[0226] As shown in Table 8, the presence of the crtB cassette in GmSMV3 resulted in a significant reduction in backbone positive events.

[0227] B) Duplicate Marker Vectors: The second strategy is to introduce a duplicated marker fragment at one end of the T-DNA, for example, adjacent to the RB (see partial marker in Figure 12B). This fragment shows homology to a marker gene present adjacent to the LB (see Figure 12B). Direct end-joining of the T-DNA does not result in a functional marker gene cassette, and single-copy insertion or multi-copy stacking does not express a functional marker gene, allowing plant regeneration under selection. Regenerated plants can only result from events in which homologous recombination occurs between the duplicated marker fragments, resulting in a reconstituted functional marker.

[0228] A GmSMV4 T-DNA vector was designed, comprising, in 5' to 3' order, a shortened left border (tLB) sequence (SEQ ID NO: 12); a 3' aadA marker cassette in a forward orientation (SEQ ID NO: 11); an expression cassette for a gene of interest (GOI 2) under the control of a non-constitutive promoter; an expression cassette for a Cas12a nuclease-encoding sequence; an expression cassette for a Cas12a gRNA targeting the GmTS3 target site in the soybean genome; a first Lox site; an expression cassette for gene of interest 1 under the control of a constitutive promoter; a 27-nucleotide sequence encoding the GmTS2 target site; a spacer sequence (SEQ ID NO: 16); a second Lox site; the 5' aadA marker cassette in a forward orientation (SEQ ID NO: 10); a sequence containing a partial fragment of the 3' aadA marker cassette in a forward orientation (SEQ ID NO: 25); and a shortened right border (tRB) (SEQ ID NO: 13). SEQ ID NO:25 is a 944 bp sequence containing the 3' Arabidopsis actin intron fused to the 5' CDS fragment from the aadA marker, showing homology to the 3' aadA marker cassette present adjacent to LB. A control vector identical to GmSMV4 but lacking the partial 3' marker cassette (SEQ ID NO:25) fragment was also generated.

[0229] Embryos excised from A3555 soybean plants were co-cultured with Agrobacterium containing the GmSMV4 vector or a control vector, and transformed plants were selected for shoot elongation on spectinomycin medium. Spectinomycin-resistant shoots were transferred to soil plugs for rooting. DNA was extracted from leaf samples and used for copy number determination by a TaqMan™-based assay. A flanking PCR assay was used to identify plants with site-specific integration of the T-DNA at the GmTS2 site. DNA from flanking PCR-positive putative targeted events was further processed for genome sequencing to confirm SDI and analyze for the presence of the vector backbone. The results are summarized in Tables 9 and 10. As shown in Table 10, the presence of a partial 3' aadA marker cassette flanking the RB resulted in a reduction of backbone vector-positive events.

[0230] [Table 9]

[0231] [Table 10]

[0232] Example 7 SDI by homologous recombination The circular T-DNA and split marker configuration can also be used for homologous recombination-directed integration, as depicted in Figure 13. Two homology arms homologous to the genomic target site are inserted between the GOI and the marker gene promoter. An internal cleavage site is located between the homologous arms. After circularization and relinearization of the T-DNA in plant cells, the exposed homology arms (HR1 and HR2) at both ends promote homologous recombination between the GOI and the genomic target site. The backbone reduction strategy described in Figure 12A and Example 6 can be included to further improve homologous recombination frequency.

[0233] Example 8 Use of Cre / lox to achieve targeted insertion This example describes the design and testing of a Cre-Circle T-DNA vector containing a Cre / lox recombinase system that is expected to induce T-DNA circularization and targeted insertion of donor DNA in the maize ZmTS1 genomic region.

[0234] In 5' to 3' order, a left border (LB) sequence; a nuclease cassette (SEQ ID NO: 26) comprising a promoter operably linked to a sequence encoding Cas12a; a guide RNA cassette (SEQ ID NO: 26) comprising a polymerase III promoter operably linked to a sequence encoding a guide RNA targeting ZmTS1; in forward orientation, a rice actin promoter (SEQ ID NO: 18), a leader (SEQ ID NO: 19), and an intron sequence (SEQ ID NO: 20); a first lox site; and ZmTS1. A T-DNA construct was generated containing a Cas12a target site, a promoter operably linked to a sequence encoding a gene of interest, a second lox site, a sequence encoding a selectable marker CP4 gene cassette containing, in forward orientation, a nucleotide sequence encoding an Arabidopsis thaliana EPSPS transit peptide (SEQ ID NO:7), followed by a coding sequence for an Agrobacterium EPSPS-CP4 reporter gene (SEQ ID NO:21) and a transcription termination sequence from the Agrobacterium nos gene (SEQ ID NO:9), a recombinase cassette containing a rice actin promoter (SEQ ID NO:18), leader (SEQ ID NO:19), and intron (SEQ ID NO:20) operably linked to a sequence encoding Cre recombinase (SEQ ID NO:13 in WO2021026165), and a right border (RB) sequence (see Figure 6).

[0235] Without being bound by any particular theory, it is hypothesized that once the construct is introduced into a plant cell via Agrobacterium-mediated transformation, the T-DNA is randomly inserted into the plant cell's genome, and expression of Cre recombinase excises and circularizes a segment of the T-DNA containing a Cas12a target site and a promoter operably linked to a sequence encoding the gene of interest. This excision then allows the promoter to drive expression of a selectable marker gene at the random chromosomal insertion site, allowing for selection of this circularized event. Cas12a cleaves the circularized T-DNA fragment, and the target site in the genome allows the GOI to integrate at the targeted chromosomal location.

[0236] Embryos of maize cultivar 01DKD2 were transformed with Agrobacterium containing the CreCircle T-DNA vector using methods known in the art. Stably transformed plants were selected against glyphosate. Leaf samples from regenerated plantlets were harvested after two weeks, and genomic DNA was extracted for copy number determination using a TaqMan-based assay known in the art. A flanking PCR assay was used to identify plants with site-specific integration of the GOI at the ZmTS1 site. DNA from flanking PCR-positive putative targeting events was further processed for genome sequencing to confirm the proportion of SDI and commercial-quality SDI. The results, summarized in Table 11, show that three SDI events were observed with the CreCircle T-DNA, one of which was a commercial-quality SDI event.

[0237] [Table 11]

[0238] Example 9 Use of Cre / lox to achieve targeted insertion A T-DNA construct is generated that includes, in 5' to 3' order, a left border (LB) sequence, a promoter operably linked to a sequence encoding Cas12a, a promoter operably linked to a sequence encoding a guide RNA, a first lox site, a sequence encoding a selectable marker gene in a forward orientation, a Cas12a target site, a promoter operably linked to a sequence encoding a gene of interest, a promoter in a forward orientation, a second lox site, a promoter operably linked to a sequence encoding Cre recombinase, and a right border (RB) sequence. See Figure 7.

[0239] The construct is introduced into plant cells via Agrobacterium-mediated transformation, and the T-DNA is randomly inserted into the plant cell's genome. Upon expression, Cre recombinase excises and circularizes a segment of T-DNA containing a promoter, a second lox site, a sequence encoding a selectable marker, a promoter operably linked to a sequence encoding a gene of interest, and a Cas12a target site. This excision then allows the promoter to drive expression of the selectable marker gene, allowing for selection of this circularized event. Cas12a cleaves the target site in the circularized T-DNA fragment and genome, allowing the forward-oriented promoter, the selectable marker gene, and a promoter operably linked to a sequence encoding a gene of interest to be integrated at the targeted chromosomal location.

[0240] Example 10 Use of Cre / lox to achieve targeted insertion A T-DNA is generated that includes, in 5' to 3' order: a left border (LB) sequence; a promoter operably linked to a sequence encoding a selectable marker gene; a polymerase III promoter operably linked to a sequence encoding a Cas12a guide RNA; a promoter in a forward orientation; a first lox site; a Cas12a target site; a promoter operably linked to a sequence encoding a gene of interest; a second lox site, a sequence encoding Cas12a in a forward orientation; a promoter operably linked to a sequence encoding Cre recombinase; and a right border (RB) sequence. See Figure 8a.

[0241] The construct is introduced into plant cells via Agrobacterium-mediated transformation, and the T-DNA is randomly inserted into the plant cell's genome. Cre recombinase is expressed, excising and circularizing a fragment of T-DNA containing a Cas12a target site and a promoter operably linked to a sequence encoding a gene of interest. After Cre recombinase-mediated excision, the promoter is operably linked to a sequence encoding Cas12a. Expression of Cas12a not only excises the circularized T-DNA fragment, but also allows the target site in the genome to be excised, thereby allowing the gene of interest to be integrated at the targeted chromosomal location.

[0242] A T-DNA is generated that contains, in 5' to 3' order: a left border (LB) sequence; a promoter operably linked to a sequence encoding a selectable marker; a promoter operably linked to a sequence encoding a Cas12a guide RNA; the promoter in a forward orientation; a lox66 site; a Cas12a targeting site; the gene of interest; a lox71 site, a sequence encoding Cas12a in a forward orientation; a promoter operably linked to a sequence encoding Cre recombinase; and a right border (RB) sequence. See Figure 8b.

[0243] The construct is introduced into plant cells via Agrobacterium-mediated transformation, and the T-DNA is randomly integrated into the plant cell's genome. Cre recombinase expression excises and circularizes the T-DNA fragment containing the Cas12a target site and the gene of interest. After excision, a forward-oriented promoter can drive Cas12a expression at the random chromosomal insertion site. Cas12a expression not only cleaves the circularized T-DNA fragment but also cleaves the target site in the genome, thereby allowing the gene of interest to integrate at the targeted chromosomal location. The purpose of using engineered lox sites in the T-DNA construct is to generate plants in which the mutant lox sites (lox66-71) in the final targeted chromosomal insertion do not recombine with the lox sites (loxP) in the randomly integrated T-DNA, thus avoiding undesired chromosomal rearrangements between the targeting event containing the gene of interest and the randomly integrated T-DNA.

[0244] Example 11 Use of Cre / lox to achieve targeted insertion A T-DNA construct is generated that includes, in 5' to 3' order, a left border (LB) sequence, a promoter operably linked to a Cas12a guide RNA, a promoter operably linked to a sequence encoding Cre recombinase, a sequence encoding Cas12a in a reverse orientation, a first lox site, a sequence encoding a selectable marker in a forward orientation, a Cas12a target site, a gene of interest, the promoter in a forward orientation, a second lox site, the promoter in a reverse orientation, and a right border (RB) sequence. See Figure 9.

[0245] The construct is introduced into plant cells via Agrobacterium-mediated transformation, and the T-DNA is randomly inserted into the plant cell's genome. After expression, Cre recombinase excises and circularizes the T-DNA fragment containing the promoter in the forward orientation, the sequence encoding the selectable marker gene in the forward orientation, and the gene of interest. After excision, the promoter is operably linked to a sequence encoding Cas12a. Expression of Cas12a allows excision of the genomic target site. This also allows the circularized T-DNA fragment to be excised, thereby allowing the promoter in the forward orientation to drive expression of the sequence encoding the selectable marker gene and for the gene of interest to be integrated at the targeted chromosomal location. The T-DNA provided in this configuration restricts Cas12a expression, allowing selection of circularized events after excision of the sequences flanking the recombination site and expression of the selectable marker gene.

[0246] Example 12 2T construct To reduce the inefficiency caused by excision frequency, a "2T" construct can be used. See Figure 10. Generally, a 2T construct contains two T-DNAs that are independently integrated into the genome. They are subcloned into a single construct in tandem (in most cases, with the right borders close to each other and in opposite orientations to maximize the possibility of generating independent T-DNA strands). In random insertion experiments, approximately 30% of the recovered plants have integration of each of the T-DNAs. In Agrobacterium, the right side of the construct (see Figure 10) can be randomly integrated to generate a T-DNA strand (#1) containing all the machinery necessary for SDI, including an expression cassette for LbCas12a, an expression cassette for gRNA, and an expression cassette for a selectable marker. The left side of the construct (see Figure 10) generates a T-DNA strand (#2) that minimally contains RB and LB elements (often of shortened length to minimize non-cargo sequences in the final insertion), a target site for an inducible nuclease, and one or more cargo elements. In some cases, the cargo is an expression cassette for a gene of interest (GOI), but more complex designs, such as those with multiple elements, are possible. Upon circularization, strand #2 is competent for SDI at the target location in the genome. Plants can be selected based on markers at the insertion of T-DNA #1 and assayed for the presence of T-DNA #2 at the target location in the genome. Assuming random integration of T-DNA #1 occurs at a distance of more than 100 cM from the target site, removal of the SDI mechanism can be achieved at high frequency by simple segregation. This method avoids the use of Cre-lox or other recombination schemes to remove the unwanted mechanism in plants.

[0247] This method is compatible with the use of multiple gRNAs, as detailed in Figure 5. The addition of that strategy to this method involves providing a novel target site in T-DNA #2 and expressing two gRNAs from T-DNA #1: one that targets the genomic site and the other that targets the novel site present in T-DNA #2. The use of a combined strategy may result in higher efficiency of targeted insertion of T-DNA strand #2.

[0248] Example 13 Two T-DNA strategies An example of a two-T-DNA strategy for site-specific integration of a gene of interest is depicted in Figure 11. Two T-DNAs can be successfully co-introduced into plants by co-expression in Agrobacterium using independent replication origins. Currently used origins are known to support different copy numbers in Agrobacterium, and as a result, origin selection can be used to influence the ratio of T-DNA strands introduced into the plant target, which can be used to optimize the frequency of the desired end product. The two-T-DNA strategy also has the advantage of involving two smaller plasmids, which can be easier to subclone and maintain. In addition, because the machinery for SDI can be provided on one plasmid, a limited number of plasmid designs containing inducible nucleases are required for optimization. Multiple constructs containing coordinated target sites and different cargoes of interest can be more easily generated (due to their shorter size).

[0249] In random insertion experiments, approximately 30% of the recovered plants have the respective integration of the T-DNA. In Agrobacterium, the first construct can be randomly integrated to generate a first T-DNA containing the machinery necessary for SDI, including an expression cassette for LbCas12a, an expression cassette for targeting gRNA, and an expression cassette for a selectable marker. The second construct generates a second T-DNA that minimally contains RB and LB elements (often of shortened length to minimize non-cargo sequences in the final insertion); a target site; and a cargo element. In some cases, the cargo is a gene of interest (GOI), but more complex designs and designs with multiple elements are possible. The second T-DNA can be inserted at the genomic target site by excision of the circularization intermediate described above. Plants can be selected based on the marker in the first T-DNA insertion and assayed for the presence of the second T-DNA insertion at the genomic target site. Assuming that random integration of the primary T-DNA occurs at a distance of more than 100 cM from the genomic target site, removal of the primary T-DNA (as well as the expression cassettes for the inducible nuclease and selectable marker) can be achieved by simple separation. This method avoids the use of Cre-lox or other recombination schemes to remove unwanted cassettes, which may be important for plant systems where that integration strategy is inefficient.

[0250] This method is compatible with the use of multiple gRNAs, for example, as detailed in Figure 5. The addition of multiple gRNAs to this method involves utilizing a novel target site in the second T-DNA and expressing two gRNAs by the first T-DNA: one that targets the genomic target site and the other that targets the novel target site present in the second T-DNA. The use of a combined strategy can result in higher efficiency of targeted insertion of the second T-DNA into the genome.

[0251] Example 14 Binary construct design This example describes the design of a construct with two gRNAs expressed from a T-DNA: one that targets a unique target site in the T-DNA and a second that targets the GmTS1 target site (SEQ ID NO: 61) in the genome (see, e.g., Figure 5).

[0252] We designed gRNA spacer sequences to target the GmTS1 target site within a soybean chromosome. Two T-DNA target sites were designed to promote microhomology-assisted annealing with the genomic target site (see Table 12). In the first design ("GmTS1-RC"), the T-DNA target site was a 27-bp sequence containing a 4-bp PAM and a 23-bp spacer sequence (SEQ ID NO: 62). Positions 1 to 19 of the spacer complement sequence are identical between the genomic GmTS1 target site and the T-DNA target site. However, positions 20 to 23 within the T-DNA target site are designed to be the reverse complement (RC) of positions 20 to 23 of the spacer complement sequence of the genomic target site to maximize the potential for microhomology with the genomic strand.

[0253] For the second design, we hypothesized that a unique target site present in the T-DNA might improve the rate of SDI if the sequence surrounding the unique T-DNA target site matched the sequence surrounding the chromosomal GmTS1 target site. Therefore, in the second design, the T-DNA target site (GmTS1-RC1 + flank) is a 91-bp sequence (SEQ ID NO: 63) containing the GmTS1-RC target site described in Design 1, flanked by a 26-bp left flank and a 38-bp right flank sequence containing chromosomal sequences flanking the GmTS1 sequence in the soybean genome.

[0254] [Table 12]

[0255] [Table 13]

[0256] Three T-DNA constructs were generated. GmSMV5 contained, in 5' to 3' order, a truncated left border (tLB) sequence; a 3' marker cassette fragment in a forward orientation (SEQ ID NO: 11); a promoter operably linked to a sequence encoding Cas12a; a promoter operably linked to a sequence encoding a guide RNA array including gRNA1 targeting GmTS1 on the chromosome and gRNA2 targeting GmTS1-RC; gene 2 of interest; a lox site; gene 1 of interest; a GmTS1-RC target site in a forward orientation (SEQ ID NO: 62); a second lox site; a 5' marker cassette fragment in a forward orientation (SEQ ID NO: 10); and a truncated right border (tRB) sequence. See Figure 5.

[0257] GmSMV6 contained, in 5' to 3' order, a shortened left border (tLB) sequence; a 3' marker cassette fragment in a forward orientation (SEQ ID NO: 11); a promoter operably linked to a sequence encoding Cas12a; a promoter operably linked to a sequence encoding a guide RNA array comprising gRNA1 targeting GmTS1 on the chromosome and gRNA2 targeting GmTS1-RC; gene of interest 2; a lox site, gene of interest 1, a "GmTS1-RC + flank" target site in a forward orientation (SEQ ID NO: 63), a second lox site, a 5' marker cassette fragment in a forward orientation (SEQ ID NO: 10); and a shortened right border (tRB) sequence.

[0258] GmSMV7 contained, in 5' to 3' order, a shortened left border (tLB) sequence; a 3' marker cassette fragment in a forward orientation (SEQ ID NO: 11); a promoter operably linked to a sequence encoding Cas12a; a promoter operably linked to a sequence encoding a guide RNA array comprising gRNA1 targeting GmTS1 on the chromosome and gRNA2 targeting GmTS1-RC; gene of interest 2; a lox site, gene of interest 1, a "GmTS1-RC + flank" target site in a reverse orientation (SEQ ID NO: 63), a second lox site, a 5' marker cassette fragment in a forward orientation (SEQ ID NO: 10); and a shortened right border (tRB) sequence.

[0259] The constructs were introduced into plant cells via Agrobacterium-mediated transformation. GmSMV1, described in Example 2, was used as a control. Inside the plant cells, a subset of T-DNAs circularized. The Cas12a-gRNA2 complex cleaved the circularized T-DNA, and the Cas12a-gRNA1 complex cleaved the genomic target site. Circularization and subsequent cleavage of the T-DNA allowed for targeted integration of the linearized T-DNA into the genomic target site. Circularization and linearization also reconstituted a spliceable intron within the marker cassette, thus allowing the promoter to drive expression of the selectable marker gene, thus enabling selection of events that underwent circularization and subsequent T-DNA integration. Flank PCR assays and genomic DNA sequencing were performed to identify plants with targeted integration events. The data are summarized in Table 14. High-quality SDI events were defined as single-copy insertion of the T-DNA at the target site with an intact cassette and approximately the expected transgene / genome junction. The SDI rate is defined as the ratio of high-quality SDI events to the sample. The rate of high-quality SDI in two-copy events indicates that these plants have two copies of TDNA, with at least one TDNA being a high-quality SDI insertion. These plants require progeny segregation for single-copy commercial-quality SDI events.

[0260] As shown in Table 14, commercial-quality SDI events were generated from all tested constructs. The highest rate of commercial-quality SDI (9.52%) was observed with the GmSMV6 construct, which contained the 91-bp "GmTS1-RC + flank" T-DNA target site in the forward orientation. The GmSMV7 construct, which contained the 91-bp "GmTS1-RC + flank" T-DNA target site in the reverse orientation, also generated a high number of commercial-quality events and had a Q-SDI rate of 4.76%. Without being bound by any theory, it is hypothesized that a potential benefit of using the larger 91-bp target site with flanks is that the target site on the T-DNA is further away from both upstream and downstream T-DNA elements that must be present in commercial-quality events, allowing for a greater likelihood of retaining their entire sequence after SDI. A second potential benefit is that flanks may promote spatial separation of the T-DNA target sequence from other T-DNA sequences / elements, some of which may have a negative effect on the functionality of the target sequence.

[0261] [Table 14]

[0262] Example 15 Use of Cre / lox to achieve targeted insertion A T-DNA is generated that comprises, in 5' to 3' order, a left border (LB) sequence, a promoter operably linked to a sequence encoding a selectable marker gene, a promoter operably linked to a sequence encoding a Cas12a nuclease, a polymerase III promoter in a forward orientation, a first lox site, a Cas12a target site, a gene of interest, a second lox site, a sequence encoding a guide RNA in a forward orientation, a promoter operably linked to a sequence encoding a Cre recombinase, and a right border (RB) sequence. See Figure 19.

[0263] The construct is introduced into plant cells via Agrobacterium-mediated transformation, and the T-DNA is randomly inserted into the plant cell's genome. When Cre recombinase is activated, it excises and circularizes a segment of the T-DNA containing a Cas12a target site and a promoter operably linked to a sequence encoding a gene of interest. After excision, the forward-oriented polymerase III promoter can drive expression of a guide RNA at the random chromosomal insertion site. Expression of Cas12a and the gRNA not only cuts the circularized T-DNA fragment, but also allows it to cut the target site in the genome, thereby allowing the promoter operably linked to a sequence encoding a gene of interest to be integrated at the targeted chromosomal location.

[0264] Example 16 Use of Cre / lox to achieve targeted insertion via homologous recombination A T-DNA is generated that includes, in 5' to 3' order, a left border (LB) sequence, a promoter operably linked to a sequence encoding a Cas12a nuclease, a polymerase III promoter operably linked to a sequence encoding a guide RNA, a first lox site, a Cas12a target site, a left homology arm (HR-L) comprising a sequence exhibiting homology to the left flank of the genomic target site, a gene of interest, a right homology arm (HR-R) comprising a sequence exhibiting homology to the right flank of the genomic target site, a second lox site, a promoter operably linked to a sequence encoding a Cre recombinase, a promoter operably linked to a sequence encoding a selectable marker gene, and a right border (RB) sequence. See Figure 20.

[0265] The construct is introduced into plant cells via Agrobacterium-mediated transformation, and the T-DNA is randomly inserted into the plant cell's genome. When Cre recombinase is activated, it excises and circularizes a fragment of T-DNA containing the Cas12a target site and the gene of interest flanked by HR-L and HR-R. Expression of Cas12a and gRNA not only cleaves the circularized T-DNA fragment but also cleaves the target site in the genome, thereby allowing the gene of interest to integrate at the targeted chromosomal location. The T-DNA fragment can be integrated at the target site via non-homologous end joining (NHEJ), which results in the maintenance of a second lox site in the integrated fragment. Alternatively, the presence of homology arms can facilitate integration of the gene of interest into the genomic target site via a homologous recombination (HR) mechanism, whereby the second lox site is not present in the integrated fragment.

[0266] Example 17 Use of Cre / lox to achieve targeted insertion via homologous recombination A T-DNA is generated that includes, in 5' to 3' order: a left border (LB) sequence; a promoter operably linked to a sequence encoding a Cas12a nuclease; a polymerase III promoter operably linked to a sequence encoding a guide RNA; a first lox site; a right homologous recombination arm (HR-R) comprising a sequence that exhibits homology to the right flank of the genomic target site; a Cas12a target site; a left homologous recombination arm (HR-L) comprising a sequence that exhibits homology to the left flank of the genomic target site; a promoter operably linked to a sequence encoding a gene of interest; a second lox site; a promoter operably linked to a sequence encoding a Cre recombinase; a promoter operably linked to a sequence encoding a selectable marker gene; and a right border (RB) sequence. See Figure 21.

[0267] The construct is introduced into plant cells via Agrobacterium-mediated transformation, and the T-DNA is randomly inserted into the plant cell's genome. When Cre recombinase is activated, it excises and circularizes a segment of the T-DNA containing the Cas12a target site and a promoter operably linked to a sequence encoding a gene of interest flanked by HR-L and HR-R. Expression of Cas12a and gRNA not only cleaves the circularized T-DNA fragment, but also cleaves the target site in the genome, thereby allowing the promoter operably linked to a sequence encoding a gene of interest to be integrated at the targeted chromosomal location. The presence of exposed HR arms can facilitate integration of the gene cassette of interest into the genomic target site via homologous recombination (HR) or microhomology-mediated end joining (MMEJ).

[0268] Example 18 Use of TALE to induce Cre expression and Cre / lox to perform targeted insertion This example describes a T-DNA vector design that utilizes TALE (transcription activator-like effector) proteins to induce expression of Cre recombinase, resulting in T-circle formation that leads to inactivation of Cre, thereby restricting expression of the recombinase. Transcription activator-like effectors (TALEs) are transcription factors that contain a C-terminal activation domain that can activate or increase expression of a gene when they bind to TALE binding site (TBS) DNA at or near the gene's promoter.

[0269] A T-DNA is generated that comprises, in 5' to 3' order, a left border (LB) sequence, a promoter operably linked to a sequence encoding a Cas12a nuclease, a polymerase III promoter operably linked to a sequence encoding a guide RNA, a promoter operably linked to a sequence encoding a TALE protein comprising an activation domain, a first lox site, a Cas12a target site, a gene of interest, a TALE binding site (TBS), a second lox site, a minimal promoter (e.g., a 35S minimal promoter) operably linked to a sequence encoding a Cre recombinase, a promoter operably linked to a sequence encoding a selectable marker gene, and a right border (RB) sequence. See Figure 22.

[0270] The construct is introduced into plant cells via Agrobacterium-mediated transformation, and the T-DNA is randomly inserted into the plant cell's genome. The TALE protein is expressed and binds to the TBS located adjacent to the minimal promoter, resulting in Cre expression. Cre recombinase excises and circularizes the T-DNA fragment containing the Cas12a target site, the gene of interest, and the TBS. Expression of Cas12a and gRNA not only cleaves the circularized T-DNA fragment, but also allows it to cleave at the target site in the genome, thereby allowing the gene of interest to integrate into the targeted chromosomal location. Excision of the T-DNA fragment results in the separation of the TBS from the Cre cassette, and as a result, Cre is no longer expressed. Restricting Cre expression can help prevent unwanted recombination events between the gene of interest after integration into the genomic target site and the remainder of the T-DNA located at another locus in the genome. Restricted Cre expression can also reduce negative phenotypes caused by Cre expression in some dicotyledonous plant species, such as soybean.

[0271] Although a preferred embodiment uses a TALE to activate Cre expression, a catalytically inactive Cas12a (dCas12a) fused to a transcription factor (TF) activation domain (dCas12a-TF) can be used in place of the TALE protein. dCas12a contains an R1226A mutation in the Nuc domain, resulting in a protein that lacks nuclease activity but retains the ability to bind to target sites in the presence of an appropriate gRNA. dCas12a-TF can be used to activate expression of Cre operably associated with a minimal promoter and an appropriate dCas12a target binding site. In another embodiment, it may be possible to take advantage of native transcription factors, eliminating the need for a TALE or dCas12a-TF cassette in the T-DNA. In such a scenario, the TBS in the T-DNA is replaced with a binding site for the appropriate native transcription factor.

[0272] Example 19 Generation of multiple circularized T-DNA fragments from a single T-DNA This example describes a T-DNA vector designed to increase the frequency of SDI by generating multiple Cre-mediated circularized T-DNA fragments from a single T-DNA vector.

[0273] In 5' to 3' order, a left border (LB) sequence; a promoter operably linked to a sequence encoding a Cas12a nuclease; a polymerase III promoter operably linked to a sequence encoding a guide RNA; a first lox site; a first right homology arm (HR-R) comprising a sequence showing homology to the right flank of the genomic target site; a first Cas12a target site; and a first left homology arm (HR-L) comprising a sequence showing homology to the left flank of the genomic target site. A T-DNA is generated that includes: a first gene of interest; a second lox site; a second HR-R arm, a second Cas12a target site; a second gene of interest; a third lox site; a third HR-R sequence; a third Cas12a target site; a third HR-L sequence; a third GOI; a fourth lox site; a promoter operably linked to a sequence encoding Cre recombinase; a promoter operably linked to a sequence encoding a selectable marker gene; and a right border (RB) sequence. See Figure 23. In the design described above, each T-DNA sequence flanked by lox sites can be excised and circularized to provide a T-DNA fragment SDI substrate. Thus, the above design generates three circularized T-DNA fragment SDI substrates.

[0274] The construct is introduced into plant cells via Agrobacterium-mediated transformation, and the T-DNA is randomly inserted into the plant cell's genome. After expression, Cre recombinase excises and circularizes the T-DNA fragment flanked by lox sites. T-circle excision can occur in a number of ways: either each T-circle substrate can be excised individually, or one large circularized T-DNA fragment is excised and then resolved into three individual circles, each containing a Cas12a target site and the gene of interest flanked by HR-L and HR-R. Expression of Cas12a and gRNA not only excises the circularized T-DNA fragment but also allows the target site in the genome to be cleaved, thereby allowing the gene of interest to integrate at the target site in the chromosome. The presence of exposed homology arms can facilitate integration of the gene cassette of interest into the genomic target site via homologous recombination (HR) or microhomology-mediated end joining (MMEJ). The presence of multiple circularized T-DNA fragments may provide more substrates for SDI, thereby increasing SDI frequency.

[0275] Example 20 Use of viral replicons to perform targeted insertions This example describes a T-DNA vector design that utilizes replicases and long intergenic region (LIR) elements from nanoviruses and geminiviruses to provide sufficiently high copy numbers of circularized fragments for efficient SDI.

[0276] ssDNA plant viruses of the Geminiviridae and Nanoviridae families replicate via a rolling circle mechanism. Replication initiator proteins / replicases (Rep) recognize domains in the large intergenic regions (LIRs) of viral DNA and nick the DNA at conserved sites found in the hairpin structures of the LIRs, promoting rolling circle replication and the generation of circular replicons. Surprisingly, it has previously been reported that geminivirus and nanovirus replicases can recognize and circularize DNA with donor sequences flanked by their cognate LIRs (see Aronson et al., 2002, The Plant Journal., 31(6), 767-775; Baltes et al., 2014, The Plant Cell, 26:1, 151-163). Furthermore, engineered geminivirus replicons containing donor DNA have been shown to promote targeted integration of donor DNA sequences when combined with targeted chromosomal breakage (see Aronson et al., 2002, The Plant Journal., 31(6), 767-775).

[0277] A geminivirus T-DNA vector is generated that contains, in 5' to 3' order, a left border (LB) sequence, a promoter operably linked to a sequence encoding a selectable marker gene, a promoter operably linked to a sequence encoding a Cas12a nuclease, a first sequence containing an LIR from the soybean spotted wilt virus geminivirus (SCSV) (SEQ ID NO: 64), a Cas12a target site, a first gene of interest, a second sequence containing an LIR from SCSV, an SCSV Rep (replicase) cassette containing a promoter operably linked to a DNA sequence encoding SCSV Rep (SEQ ID NO: 65), a polymerase III promoter operably linked to a sequence encoding a guide RNA, and a right border (RB) sequence. A control vector of the same design but lacking the Rep cassette is also generated.

[0278] A nanovirus T-DNA vector is generated, comprising, in 5' to 3' order, a left border (LB) sequence, a promoter operably linked to a sequence encoding a selectable marker gene, a promoter operably linked to a sequence encoding a Cas12a nuclease, a first sequence comprising an LIR from the broad bean necrotic yellows virus (FBNYV) (SEQ ID NO: 66), a Cas12a target site, a first gene of interest, a second sequence comprising an LIR from FBNY, an FBNY Rep cassette comprising a promoter operably linked to a DNA sequence encoding FBNY Rep (SEQ ID NO: 67), a polymerase III promoter operably linked to a sequence encoding a guide RNA, and a right border (RB) sequence. A control vector of the same design but lacking the Rep cassette is also generated. See Figure 24.

[0279] The test and control constructs are introduced into plant cells via Agrobacterium-mediated transformation. The T-DNA is randomly inserted into the plant cell's genome. Successful expression of viral Rep proteins from the test construct is expected to circularize the fragment of the construct containing the gene of interest flanked by LIRs. Expression of Cas12a and gRNA not only cleaves the circularized T-DNA fragment, but also allows it to cleave the target site in the genome, thereby allowing the gene of interest to integrate at the targeted chromosomal location.

[0280] The advantage of using a T-DNA vector containing a viral replicase-LIR element is the possibility of generating a high-copy circular fragment containing the GOI cassette in the cell nucleus in the presence of viral replicase proteins. This, in turn, improves the rate of SDI. Viral replicase-mediated enrichment in SDI can be demonstrated in a statistically significant manner by a higher integration rate in the test compared to the control.

[0281] Example 21 Intron for split marker vector This example provides examples of monocot introns that can be used in place of the actin intron (SEQ ID NO: 22) used in the maize split marker vector described in Example 3.

[0282] [Table 15]

Claims

1. (a) Left boundary (LB) sequence; (b) a first recombination site and a second recombination site; (c) a target site for an inducible nuclease; (d) the sequence of interest; and (e) Right Boundary (RB) Array A recombinant nucleic acid construct comprising: A recombinant nucleic acid construct, wherein a target site for an inducible nuclease and a sequence of interest are located between a first recombination site and a second recombination site.

2. The recombinant nucleic acid construct described in claim 1, further comprising an expression cassette encoding at least one selectable marker.

3. The recombinant nucleic acid construct further comprises a sequence encoding an inducible nuclease operably linked to the promoter; The recombinant nucleic acid construct of claim 1, wherein the inducible nuclease is selected from the group consisting of RNA-guided nucleases, zinc finger nucleases, meganucleases, transcription activator-like effector (TALE) nucleases, and TALE-like proteins.

4. 3. The recombinant nucleic acid construct of claim 2, wherein the expression cassette encoding the at least one selectable marker comprises: (a) a promoter; (b) at least one intron; and (c) a protein coding sequence.

5. 5. An expression cassette as defined in claim 4, wherein the promoter is located between the sequence of interest and the RB sequence, and the protein coding sequence is located between the LB sequence and the sequence of interest.

6. at least one intron comprises a single intron sequence divided into two or more intron sequences; 5. The expression cassette as defined in claim 4, optionally wherein the single intron sequence is selected from the group consisting of SEQ ID NOs: 22, 68, 69, 70, 71, and 72.

7. 2. The recombinant nucleic acid construct of claim 1, wherein LB, RB, or both are truncated border sequences.

8. The recombinant nucleic acid construct, further comprising a sequence encoding at least one recombinase, 2. The recombinant nucleic acid construct of claim 1, wherein optionally, the at least one recombinase is selected from the group consisting of Cre recombinase, FLP recombinase, Gin recombinase, Tnp1 recombinase, Bxb1 integrase, phiC31 integrase, R4 integrase, and TP-901 integrase.

9. A recombinant nucleic acid construct comprising the following components in 5' to 3' order: a second promoter, a first recombination site, a target site for an inducible nuclease, a sequence of interest, a second recombination site, and at least one sequence encoding a selectable marker, wherein the second promoter and the at least one sequence encoding the selectable marker are in the same orientation; or 3. The recombinant nucleic acid construct of claim 2, wherein the recombinant nucleic acid construct comprises the following components in 5' to 3' order: a first recombination site, a sequence encoding at least one selectable marker, a target site for an inducible nuclease, a sequence of interest, a second promoter, and a second recombination site, wherein the second promoter and the at least one selectable marker gene are in the same orientation.

10. The recombinant nucleic acid construct, further comprising a sequence encoding one or more guide RNAs (gRNAs) operably linked to a Pol III promoter, optionally wherein the sequence encoding the one or more gRNAs encodes a first gRNA capable of hybridizing to a target site for an inducible nuclease in the recombinant nucleic acid construct; 2. The recombinant nucleic acid construct of claim 1, further optionally comprising a sequence encoding a second gRNA capable of hybridizing to a target site in the genome of the plant, the target site in the genome of the plant being different from the target site for the inducible nuclease in the recombinant nucleic acid construct.

11. The recombinant nucleic acid construct further comprising a first homology arm (HR1) and a second homology arm (HR2), Optionally, the target site for an inducible nuclease is located between HR1 and HR2.

12. The recombinant nucleic acid construct of claim 1 , wherein the inducible nuclease is capable of cleaving a genomic target site.

13. 1. A method for editing the genome of a plant cell, comprising: For example, the plant cell is selected from the group consisting of a corn cell, a rice cell, a soybean cell, a canola cell, an alfalfa cell, a sorghum cell, a wheat cell, a barley cell, a millet cell, a rye cell, a sugarcane cell, a cotton cell, a tomato cell, an onion cell, a cucumber cell, an Arabidopsis cell, and a potato cell; (a) providing to at least one plant cell a recombinant nucleic acid construct according to any one of claims 1 to 12; (b) selecting at least one plant cell from step (a), wherein the at least one plant cell comprises the first sequence of interest to be inserted into the genome of the plant cell; and Optionally, (c) regenerating a plant from at least one plant cell selected in step (b). A method comprising:

14. 13. A plant cell comprising a recombinant nucleic acid construct according to any one of claims 1 to 12.

15. (a) Left boundary array; (b) a first recombination site and a second recombination site; (c) a target site for an inducible nuclease; (d) the sequence of interest; and (e) Right Boundary Array 1. A method comprising the step of introducing into a cell a recombinant DNA construct comprising: A method in which a target site for an inducible nuclease and a sequence of interest are located between a first recombination site and a second recombination site, the inducible nuclease cleaves the target site for the inducible nuclease and the genomic target site, and the sequence of interest is inserted into the genomic target site.